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Abstract 
Psychosocial and Oxidative Stress and Health of Adults 
Francis Boateng Annor 
The role of stress (both psychosocial and oxidative) in the pathophysiology of several chronic 
diseases has been documented and has become a focus for chronic disease prevention and 
management. Although, psychosocial stress (PS) and oxidative stress (OS) have different 
mechanisms through which they impact health, they both cause physiological imbalance which 
might subsequently lead to a disease state. Laboratory and observational studies have linked both 
stresses to the pathophysiology of diabetes mellitus (DM) and hypertension. However, findings 
from previous studies have not been entirely consistent and results have varied based on the 
study population and the stress-measurement tool used. Given the gaps in the literature, three 
studies were conducted to examine: (1) the relationship between PS and glycemic control; (2) the 
association between PS and estimated glomerular filtration rate (eGFR); and (3) the association 
between OS and hypertension among adults.  
In the first two studies, a longitudinal data from Kaiser Permanente Georgia (KPGA) survey on 
Health and Healthy Behaviors linked to patients’ laboratory and pharmacy records was used. In 
the third study a cross-sectional data from Study on Race, Stress and Hypertension was used. 
The first study examined the association between baseline measure of work-related PS and 
glycemic control using both cross-sectional and longitudinal designs. None of the four PS sub-
scales or the overall PS measure at the work environment was significantly associated with 
glycemic control at either study baseline or over time. The second study examined the 
association between general measures of PS and changes in estimated glomerular filtration rate 
(eGFR) over time in a structural equation model framework. No significant direct association 
was observed between general PS measure and eGFR decline. However, age, race, mean arterial 
pressure and insulin use were found to be associated with eGFR decline. The third study 
examined the association between hypertension and: 1) four markers of OS (F2-Isoprostanes, 
Fluorescent oxidative products, copy number of mitochondrial DNA and Gamma-tocopherol); 
and 2) plasma nutrient based oxidative balance score (OBS). The OBS was inversely associated 
with hypertension, but none of the OS markers was significantly associated with hypertension 
after adjusting for study covariates. 
The current work highlights some of methodological issues in the assessment of PS to examine 
their relationship with DM control and complications. The study also highlights the need for 
more future studies to be conducted to confirm the association between OBS and hypertension, 
preferably longitudinal studies.  If future studies confirm this finding, then the mechanisms by 
which OBS may influence risk of hypertension would need to be explored further.   
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CHAPTER 1. INTRODUCTION AND BACKGROUND 
 
Introduction 
 
Diabetes mellitus (DM) and high blood pressure/hypertension are two common and costly 
chronic conditions that significantly increase the risk of nephropathy, cardiovascular events and 
death [1-6]. Although both conditions have several risk factors, an imbalance to the internal 
environment or a threat to the balance, known as stress, is considered a factor that impacts both. 
In the current study, we will consider psychosocial stress with respect to DM while consideration 
will be given to oxidative stress in relation to hypertension.  
DM is a chronic metabolic condition associated with elevated blood glucose level. It is usually 
caused by insulin deficiency that is often associated with insulin resistance [7]. An estimated 366 
million people worldwide, representing 8.3% of the global adult population aged 20 – 79 years 
had DM in 2011 [8]. The current prevalence is expected to increase to 10% (552 million) by 
2030 [8-11]. The prevalence of DM in the US is not different from the global estimate. An 
estimated 8.3% (25.8 million) of adults in the US had DM in 2011 [12]. In addition to the high 
DM prevalence, the age of onset, particularly, for type 2 DM has significantly declined in recent 
years [13], a development which has a serious implication on quality of life for individuals with 
early DM onset, cost associated with management, and complications that may arise from the 
disease.  
Although strong connection exists between genetic factors and DM etiology [14-16] the evidence 
points to the external environmental factors such as diet and sedentary behaviors to be the main 
culprits in the current surge in DM incidence and complications [17-19]. Therefore, most DM 
management research have focused on these traditional risk factors such as poor dietary habit, 
  
2 
 
physical inactivity and obesity but these factors have not entirely explained the variability in DM 
management and complications. Research have also noted an important role of psychosocial 
stress in DM etiology, management and complications [20, 21], however, research on 
psychosocial tress and DM management is sparse and results have been inconsistent. Beside their 
role in DM onset, the DM traditional risk factors as well as psychosocial stress also contribute to 
poor glycemic control and the risk of complications from the disease [22-24]. In an era of 
increased life expectancy but decreased age of DM onset [25], the importance of optimal DM 
control cannot be overemphasized.  Good DM management is crucial for improving overall 
quality of life, while decreasing the long term complications among DM patients. Of importance 
to the current research is the fact that psychosocial stress in modern society is increasing [26] 
while the buffering context such as the social support and the physical environment in which 
they occur is changing [27-29]. Understanding the dynamics of psychosocial stress in relation to 
glycemic control and subsequent complications from DM will lead to improved DM 
management and care.  
The prevalence of high blood pressure/hypertension is high with approximately 31% of US 
adults having the condition [30]. The current direct annual medical cost is approximately $70 
billion but it is expected to triple by 2030 [31]. The traditional risk factors for hypertension 
include family history, age, physical inactivity, obesity, tobacco use, and excessive alcohol 
intake [32-34]. These factors have also not completely explained the pathophysiology of 
hypertension. Evidence from recent studies have suggested a significant role of oxidative stress 
(OS) in the pathogenesis of hypertension [35-38].  Although, basic science and animal studies 
have supported the role of OS in hypertension [39-41], the results from human studies have not 
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been entirely consistent and protective effects of anti-oxidant supplementation to reduce blood 
pressure have not proven to be beneficial in clinical trials [42-44]. 
Based on the considerations of limited research and inconsistent findings from studies that have 
examined the relationship between psychosocial stress and DM management and complications, 
as well as the relationship between oxidative stress and hypertension/high blood pressure,  the 
overarching goal of this dissertation is to fill in some of the knowledge gaps. Specifically, the 
aim of the current study is to examine the relationships between psychosocial stress and DM 
management and complications on one hand and the relationship between oxidative stress and 
hypertension on the other hand. The study aim will be addressed through three specific research 
questions: 1) are high levels of psychosocial stress (at the work environment) associated with 
poor glycemic control among individuals with DM; 2) are high levels of general psychosocial 
stress associated with decline in estimated Glomerular Filtration Rate (eGFR); 3) is oxidative 
stress associated with hypertension? These research questions will be answered using data from 
two previously conducted studies. 
 
Background 
Psychosocial Stress, DM management and complications 
Living organisms adapt to and survive in their environment by maintaining a balance that is 
constantly challenged by complex array of internal and external forces/threats. This balance or 
equilibrium is maintained by the counteracting forces that may involve both the physical and 
mental forces to react to the threats in order to establish and re-establish balance/homeostasis 
[45, 46]. An actual or perceived threat to the maintenance of this balance/homeostasis is what 
Chrousos referred to as stress [47].   
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The historical background of psychosocial stress 
The concept of psychosocial stress is old and its meaning has changed over time. The 
contemporary stress concept begun about two millennia ago when Heracleitus suggested that 
there is an inherent capacity for all things to undergo a constant change [45]. A century later, 
Hippocrates defined a disease state as a systemic disharmony of systems of balances [45, 48].  
Hippocrates system of balance was later extended by Thomas Sydenham who suggested that the 
adaptive response to those systems could also cause pathological changes[49]. In the early 19th 
century, the principle of physiological equilibrium was suggested and the term homeostasis was 
coined to describe the physiologic processes that maintains this balance state [50]. In the 1930s, 
Selye described the general adaptation syndrome [51] using the term ‘stress’ to describe the 
mutual action of forces that take place in the body. In his ‘Stress and the general adaptation 
syndrome’ (GAS), Selye identified three phases of the stress response development; the ‘Alarm 
reaction’ (AR) that prepares the organism for fight or flight, the resistance stage during which the 
organism develops resistance to stress if it survived, and the stage of exhaustion, where 
prolonged stress leads to decreased ability to resist [51, 52].  In the late 80s, Sterling and Eyer 
(1988) introduced the concept of allostasis to describe the active process by which living 
organisms adapt to potential threats and changes in their environment in order to maintain 
homeostasis and promote survival [53]. Five years later, McEwen expanded on the concept of 
allostasis noting that when the body anticipates a stress response and shifts the homeostatic set 
point, the shift comes at a cost because it affects other physiological systems and processes. 
McEwen also coined the term ‘allostatic load’ to ‘refer to the sequelae of overactivity and 
dysregulation of the network of allostasis’ [54, 55]. The concepts of allostasis and allostatic load 
have implications on the physiological processes that explains the relationship between stress 
and chronic diseases[56]. It is important to note that stress is the body’s mechanism to maintain 
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homeostasis but chronic activation of the stress process can have serious deleterious effect on the 
body. Selye made a clarification that not all stressful conditions have deleterious effects on 
health, by describing ‘eustress’ as a good stress that could cause good feelings and help in human 
growth and development [57]. In  the early 90s, Chrousos and Gold defined stress as a state of 
disharmony, or a threatened homeostasis [45]. Most recently, Bao and colleagues have defined 
stress to be the consequence of the failure of an organism to respond appropriately to emotional 
or physical threats, whether actual or perceived [57]. The term stress and psychosocial stress 
have been used interchangeably in the literature. 
The stress system and response 
The concept of stress is broad but overall, stress may be thought of as (1) a physiological 
response to an external stimuli, (2) a psychological response to an external stimuli or (3) an 
encounter of a negative or positive  stressful life events [58]. The response to stress comes from 
the body’s reaction to physical, biological and or socio-cultural stimuli that results in adaptive 
activity [59]. The symptoms of stress may manifest as cognitive, emotional, physical or 
behavioral responses [51, 57, 60, 61]. Some cognitive symptoms of stress include poor judgment, 
low self-esteem, and poor concentration, while some emotional signs include moodiness, feeling 
of anxiety, excessive worrying, irritability, and feeling of loneliness. Physical stress symptoms 
include aches and pains, diarrhea or constipation, nausea, dizziness, and chest pain while 
behavioral symptoms may include eating little or too much, sleeping little or too much, social 
withdrawal, procrastination or neglect of responsibilities [61-63].  
Several factors influence individuals’ response to a stressful situations, adaptation to stress, and 
the impact it might ultimately have on health [64, 65]. Factors that might impact stress 
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experience include culture, religion, race/ethnicity, the number of times experienced the stress, 
and the source of stress such as poverty, major life events, abuse or trauma [65-68]. 
Figure 1.1. A schematic representation of the physiological and behavioral response to stress. 
Reproduced with permission from N. Engl J. Med (1998) [65], Copyright Massachusetts Medical 
Society  
 
 
 
 
 
 
 
 
The stress response system is highly complex and involves both the central and peripheral 
nervous systems. Four components of the central part are involved: the parvocellular neurons 
which secretes corticotropin-releasing hormone (CRH); the neurons of the paraventricular nuclei 
(PVN) of the hypothalamus which secrete arginine vasopressin (AVP); the CRH neurons, which 
form the paragigantocellular and parabrachial nuclei of the medulla and the locus caeruleus (LC) 
and; other neural groups in the medulla and pons (LC/norepinephrine (NE)) which secret NE. 
Three components of the peripheral part are also involved: the neuroendocrine hypothalamic-
pituitary-adrenal axis (HPA axis); the efferent systemic sympatheticadrenomedullary systems; 
and the part functioning under the control of the parasympathetic system [49]. Several changes 
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and interactions occur in the two systems during stressful situations, all of which are geared 
towards re-establishing a state of homeostasis. Within the central nervous system, the changes 
that occur activates and enables neural pathways to facilitate functions such as arousal, vigilance, 
cognition, focused attention, and appropriate aggression while concurrently inhibiting pathways 
that promotes vegetative functions. The changes to the peripheral system also occur to redirect 
energy to the central nervous system and the sites under stress [47, 69, 70]. Many sites of these 
two systems engage in lots of interactions through reciprocal neuronal connections as indicated 
by Figure 1.2 [49, 71].  
Two major components mediates this general adaptation response as described by Selye; the 
corticotropin releasing hormone (CRH) and the locus ceruleus-norepinephrine (LC-
NE)/autonomic nervous system [47, 49]. The paraventricular nucleus of the hypothalamus is 
mostly associated with the CRH component. The CRH action includes the activation of the 
HPA-axis and the sympathetic nervous system, thus, increasing the level of glucose, heart rate 
and blood pressure. The activation of the LC-NE system leads to the release of NE from neurons 
located throughout the brain to enhance arousal and vigilance, and to also increase anxiety. The 
sympathetic division of the autonomic nervous system also helps in adaption through its 
effectors - the sympathetic nerves and the adrenal medulla during response to stress. The 
parasympathetic division of the autonomic nervous system also produces negative effects to 
those of the sympathetic nervous system[47].  
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Figure 1. 2. A schematic summary of the central and peripheral components of the stress system 
[49]. 
 
In encountering an acute stressor, the HPA-axis and the sympathetic nervous system (SNS) 
produce stress hormones. The PVN produce corticotropin releasing factor, which in turn 
stimulates the pituitary to produce adenocorticotropin. The adenocorticotropin also stimulates the 
adrenal cortex to secrete cortisol. In parallel, the SNS also stimulates the adrenal medulla to 
produce catecholamines [72]. The cortisol and the catecholamines together,  increases the 
availability of energy by stimulating lipolysis and glycogen to glucose conversion [72]. The 
available energy is then distributed to essential organs such as the brain and the skeletal muscles 
by increasing blood pressure levels. In addition, the immune system gets activated and the cells 
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of the innate immune system enters the blood stream from the spleen and the lymphatic tissues, 
migrating to tissues likely to sustain injury during physical confrontation [73]. When a stressor 
become chronic, the stress system become continuously activated. The response to such chronic 
stressor can become maladaptive and may lead to a disease state [52]. 
Psychosocial Stress, DM management and complications – the link 
Psychosocial stress impacts DM management and complications through two proposed 
mechanisms - physiological and behavioral. 
The physiologic mechanism 
The physiological part of the stress system that affects diabetes management and complications 
include the autonomic nervous system, the neuroendocrine system, and the immune systems 
[74]. The cortisol released during stressful situation has been found to antagonize the actions of 
insulin and fat deposition [58, 75]. Under normal conditions, cortisol production follows a 
circadian trend where its levels are highest in the morning but subsides as the day goes by.  
However, when exposures to stress become chronic, excess cortisol get released to maintain 
homeostasis. The implication is that the constant activation of the biochemical processes that 
follow the activation of the HPA axis directly affect insulin uptake and fat deposition and thus, 
impacts blood glucose level. Cortisol is also known to have an immunosuppressive effect and 
therefore plays a role in the regulation of immune and inflammatory processes [58, 76]. The 
catecholamines released during stressful situations are believed to promote hyperglycemia 
among individuals with DM by blocking insulin action and stimulating hepatic glucose 
production. Thus, stress-related neuroendocrine activity might create or sustain hyperglycemic 
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conditions [77]. It has also been suggested that stress leads to increased visceral adiposity, a 
factor that has consistently been associated with insulin resistance [78]. 
Behavioral mechanism 
Psychosocial stress has been indirectly associated with DM control and complications through 
the difficulties in self-care, inadequate medication adherence, and risky lifestyle behaviors - all 
of which affect glycemic control and risk of vascular complications [79-83]. It is important to 
mention that the effect of stressful experiences on behavior to impact diabetes management and 
complications varies from person to person and it is impacted by several factors [84].  
Literature on Psychosocial Stress, DM management and complications 
Among DM patients, sustained hyperglycemia or fluctuations in blood glucose, an indication of 
poor glycemic control have been associated with the initiation, sustenance and progression of 
DM related complications [85-90].  
Initial laboratory studies demonstrated that stressful situations such as unpleasant interviews or 
impending examinations destabilized blood glucose levels [91]. Later clinical studies 
corroborated the initial laboratory findings.  For instance, Aikens (1992) observed that daily 
psychosocial stress was significantly associated with poor glycemic control and that the 
mechanisms of this association included both the direct effect on glucose levels and indirect 
effect on treatment adherence [77].  Peyrot and colleagues also found poor glycemic control 
among 105 adult DM patients who had higher levels of stress [92]. Peyrot et al noted that a good 
stress coping mechanism could offset the deleterious effect of stress on glycemic level [92]. 
Similarly, Suwit et al. observed that a good stress management program confers clinically 
significant benefits to individuals with DM through good glycemic control [22]. In assessing a 
variety of life events as well as long term difficulties, Lloyd found a significant association 
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between stress and poor glycemic control noting that participants whose glycosylated 
hemoglobin (HbA1c) level increased or remained high were significantly more likely to have 
experienced severe personal stressors in the previous three months [23].  A more recent study 
evaluating the psychosocial burden of  Japan’s Great East Earthquake found a significant 
independent association between stress and poor glycemic control among DM patients [93]. 
Although the majority of the studies noted a significant association between stress and glycemic 
control, the results have not been entirely consistent. Gois and colleagues, for instance, did not 
find a significant association between stress vulnerability and poor glycemic control [94]. 
Similarly, Trief and colleagues also did not find an association between work-related stress and 
glycemic control [95].  
Among DM patients, good glycemic control could delay the onset and slow the progression of 
complications related to DM such as diabetes nephropathy (DN) [86, 96, 97]. However, some 
DM patients with poor glycemic control never develop DN while some with good glycemic 
control progresses to DN [85]. Such occurrence demonstrates that factors other than glycemic 
control may be important for renal decline and subsequent progression to DN among individuals 
with DM. Genes have been identified as one factor since there is a strong familial risk for DN; 
however, there has been a limited success in identifying specific genes that account for such 
predisposition among large DM population [98, 99]. Other risk factors found to influence the 
initiation, sustenance, and progression of DN include high blood pressure and smoking but they 
have not been able to entirely explained the variability in the onset and progression of DN among 
DM patients [100-102].  
Psychonephrologist (social nephrologic scientists), have hypothesized that chronic stress may be 
may impact the development of CKD [103, 104]. Such reasoning is plausible, the fact that stress 
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has been found to increase in the engagement of some CKD related risk behaviors such as 
alcohol use and abuse, tobacco and drug use [81, 105, 106]. The relationship between 
psychosocial stress and renal decline among DM patients has not been adequately investigated. 
The gaps in knowledge  
First, as noted in the literature, finding from studies on the association between psychosocial 
stress and glycemic control remains inconclusive. This calls for more studies to be conducted to 
further examine this relationship. Secondly, limited studies have examined the relationship 
between glycemic control and psychosocial stress from a specific source, particularly, from the 
work environment. The majority of the studies to date have examined the relationship between 
general psychosocial stress and glycemic control. However, workplace is becoming increasingly 
relevant to health in the contemporary society where the majority of adults spend eight or more 
hours a day and five or more days a week. Therefore, understanding the relationship between 
psychosocial stress at the work environment and glycemic control is crucial for work place 
policies that might contribute to good DM management. To the best of our knowledge, the 
research on the association between psychosocial stress at the work environment and glycemic 
control is limited to the unique study by Trief and colleagues [95]. The study did not find an 
overall significant association between the factors. However, the study had some limitations; 
small sample size, cross-sectional study design and the DM patients in the study were all insulin 
requiring, an indication that the study participants, particularly those with type 2 DM had poor 
glycemic control and or have had the condition for a long time. Thirdly, although it has been 
hypothesized that psychosocial stress would be associated with DM complications such as DN, 
this hypothesis has not been adequately tested. Fourth, the measurement errors associated with 
the various stress sub-scales is considered a major reason for the limited research in this area. 
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The use of statistical models that will reduce the measurement errors such as latent variable 
analysis have not been adequately utilized. Finally, most of the studies published to date had 
small sample size. For instance all but one of the studies reviewed had a sample size of under 
130 participants. This study will address some of these gaps identified in the literature. 
 
Oxidative stress, oxidative balance score and hypertension 
Oxidative stress (OS) has been defined as an imbalance between pro-oxidants and anti-oxidants 
in favor of the former [107]. This imbalance leads to damages in essential biomolecules such as 
proteins, lipids and DNA [108-110]. Pro-oxidants are factors that promote the generation of 
reactive oxygen species (ROS) while anti-oxidants counteracts the actions of ROS. 
Overproduction of ROS or impairment in their removal is the cause of the imbalance.  
ROS are produced endogenously either as a by-product of aerobic metabolism or oxidative 
phosphorylation [111-113]. Exogenously, ROS may be produced in response to some 
environmental exposure such as ionizing radiation, inflammation, alcohol and smoking [114-
119]. To maintain homeostasis, living organisms use several strategies, both enzymatic and non-
enzymatic, to neutralize the deleterious effect of ROS [120].  Enzymatic anti-oxidants include 
superoxide dismutase (SOD), catalases (CAT) and glutathione peroxide (GSH-Px) [121]. Non-
enzymatic anti-oxidants include a variety of exogenous biological molecules such as 
gluthathione, vitamin C, vitamin E, flavonoids, polyphenols and carotenoids [122, 123]. An anti-
oxidants system may work to either prevent the formation of ROS (primary anti-oxidants) or 
react with the ROS to neutralize or inhibit their actions (secondary anti-oxidants) [124]. OS have 
been implicated in several disease states in humans including vascular diseases [125-127]. 
Hypertension has been associated with higher levels of OS, although the debate still exists 
whether the increased levels of OS is a cause or a consequence of hypertension [128].  
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Figure 1.3. Major sources of anti-oxidants in the body and their consequence [121]. 
 
 
The majority of the evidence supporting the relationship between OS and hypertension are from 
basic science and animal studies [39-41]. In humans, however, the results have not been entirely 
consistent and the efficacy of anti-oxidants supplementation in reducing blood pressure have not 
proven much benefits in clinical trials [42, 43]. Few smaller studies, have however, observed 
limited benefits of certain anti-oxidants in reducing blood pressure [129, 130]. 
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Oxidative Stress and Hypertension 
ROS has been identified as a major player in blood pressure regulation through their activities in 
the homeostasis of the vascular wall [131, 132]. A variety of sources of ROS exists in the blood 
vessel including NOX and NO synthase [133]. ROS effect on vascular tone are mediated through 
redox-sensitivity regulation of multiple signaling pathways and second messengers [134]. OS 
relates to hypertension through an impaired endothelium-dependent vasodilation with 
inactivation of endothelium-derived nitric oxide by oxygen free radicals [128, 133].  
The endothelial cells are important in the relaxation of arterial walls [135] through the release of 
NO by agents such as acetycholine in the vascular vessel to cause vascular relaxation [136, 137]. 
The biosynthesis and bioavailability of NO to perform this function is mostly dependent on the 
oxygen derived free radical superoxide anion which rapidly degrades them [138]. In addition, the 
nitric oxide synthase (NOS), specifically, the endothelial isoform (eNOS) which generates NO 
under normal cellular functioning also generate superoxide [139] in response to artheriogenic 
stimuli in a process termed “NOS uncoupling”, which refers to the decrease in NO enzyme 
activity due to increase in NOS-dependent superioxide activity [140]. NOS uncoupling could 
also occur under conditions of depleted tetrahydrobiopterin (BH4), a cofactor and L-arginine, a 
substrate to eNOS [140]. There is an evidence of the depletion of these cofactors during OS 
which results in eNOS uncoupling [37, 140]. Beside their role in degrading the NO, superoxide 
anions are also vasoconstrictors and may therefore modify the endothelial function [37].  
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is a major source of ROS in the 
vasculature [141, 142]. The activity of NADPH oxidase is upregulated by hormones such as 
Angiotensin II (AT-II), endothelin-1 (ET-1) and urotensin II (UT-II), thus, increasing the 
production of ROS [131]. These hormones are also capable of exerting an array of physiological 
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effects by mediating other processes that have the potential to alter arterial pressure as indicated 
by Figure 1.4 [143]. Ang II also stimulates hypertension by decreasing NO biosynthesis through 
the down-regulation of soluble guanylyl cyclase which impair NO/cyclic guanosine 
monosphosphate signaling [137]. NADPH oxidase-driven generation of ROS leads to the 
formation of peroxynitrate that causes eNOS uncoupling to produce more ROS. Peroxynitrate 
also causes the inactivation of the NO [144]. NO also not only suppress the effect of AT-II, it 
also down regulate the activity of angiotensin converting enzymes (ACE) and AT1 [141].  
Figure 1.4. Schematic summary of the role of vascular oxidative stress in pathogenesis of 
hypertension [141]. Used with permission from Macmillan Publishers Ltd: Journal of 
Hypertension Research. 
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Anti-oxidants, oxidative balance score and hypertension 
Anti-oxidants are compounds that are able to trap ROS and thus may be capable of reducing 
oxidative damages and possibly, blood pressure [138]. They scavenge on free radicals. They act 
as reducing agents (so they get oxidized) to terminate the actions of ROS by removing free 
radical intermediates, and inhibiting other oxidation reactions [37, 145]. Antioxidants include 
agents such as carotenoids, vitamin E, vitamin C, and selenium [146]. Dietary carotenoids are 
obtained from consuming green and yellow vegetables such as sweet potatoes, spinach and 
carrots. The major carotenoids include α-carotene, β-carotene, lycopene, leutin, β-cryptoxanthin 
and zeaxanthin [147].  
The intake of diets rich in anti-oxidants have been found to reduce blood pressure in both 
normotensives and hypertensives and resulted in increased blood anti-oxidants capacity [148]. 
The Dietary Approaches to Stop Hypertension (DASH) study for instance, found diet rich in fruit 
and vegetable to reduce clinical and ambulatory blood pressure in hypertensive and 
normotensive subjects than the control diet [149]. A follow-up to the DASH study also noted that 
the modified diet increased serum anti-oxidants capacity and decreased malondialdehyde, a 
biomarker of OS [150]. A 6-months blood pressure intervention among hypertensives using 
fruits and vegetables (consumption of 5 servings of fruits and vegetables daily) found a reduction 
in both systolic and diastolic blood pressure, and noted an increase in plasma level α- and β-
carotene, lutein, β-crytoxanthin, and vitamin C [151].  
While dietary antioxidants seem to have beneficial effects on blood pressure, antioxidant 
supplementation have shown to be ineffective or even dangerous in clinical trials [152]. The 
reasons for this discrepancy include: 1) the trial designs; 2) patients cohorts; 3) type of anti-
oxidants; 4) and the dosage of anti-oxidants [36]. One other possible reason is that in diets, 
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antioxidants are mixed and work as continuous chain while supplementation are usually one or 
two specific anti-oxidants and therefore, lacks this anti-oxidants chain. Also, if an antioxidant is 
not restored by the next in the chain after scavenging ROS, it begins to act as a pro-oxidant 
[153]. The evidence therefore suggests that biochemical interactions exists in dietary 
antioxidants which may be lacking in supplements due to the use of one or two individual 
antioxidants [154, 155].  
To account for the complex relationship that may exist among various pro- and anti-oxidants and 
to overcome the limitations of analyzing independent OS exposures, some researchers have 
proposed combining known individual pro- and anti-oxidants available to a score, termed by van 
Hoydonck and colleagues as ‘Oxidative Balance Score’ (OBS) [156]. The OBS has been 
associated with the risk of cancer mortality [157-159]. Studies on the relationship between OBS 
and hypertension is sparse.  
Measure of Oxidative Stress  
OS cannot be directly observed in vivo, due to the short lifespan of reactive oxygen species. They 
can be assessed using biomarkers [160].  Numerous biomarkers of OS have been proposed. 
While some are non-specific, others measure specific biochemical aspect of the process [161, 
162]. Four OS markers that are important to hypertension studies include F2-isoprostanes (F2-
isoP), fluorescent oxidative products (FOP), copy number of mitochondrial DNA (MtDNA) and 
γ-tocopherol (γ-Toc).  
F2-isoP is a validated biomarker of OS and considered a gold standard OS marker [163].  They 
are prostaglandin-like substances that are produced in vivo, primarily by free radical-induced 
peroxidation of arachidonic acid, independently of cyclooxygenase enzymes [164]. The product 
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represents the level of lipid peroxidation in OS. High levels of F2-isoP has been associated with 
cardiovascular disease [135].   
FOP is considered a non-specific marker of OS that measures a mixture of analytes resulting 
from reactions of reactive oxygen species with lipids, proteins and or DNA [165]. It is comprised 
of fluorescent conjugated Schiff bases that are formed when malonaldehyde, a byproduct of lipid 
peroxidation, reacts with amino groups [165]. Its use in human studies is relatively new. A study 
found FOP to be an independent predictor of coronary heart disease in humans [166]. 
The use of MtDNA as an OS marker is also relatively new. The copy number of MtDNA has 
been found to alter in response to OS [167], increasing its copy numbers during OS [168, 169]. 
The MtDNA has a limited repair capability and compensate for damage by increasing its copy 
numbers [170]. Higher copy numbers of MtDNA has been associated with the risk of developing 
prostate cancer [171]. 
γ-Toc is an isomer of vitamin E with two methyl groups on the phenol ring[172]. It has been 
characterized as an antioxidant defense indicator whose level increases to reflect metabolic 
response to OS [173].  Plasma levels of  γ-Toc has been inversely associated with cardiovascular 
disease [174].  
OBS has also been used to represent the overall oxidative burden as initially proposed by van 
Hoydonck and colleagues  [156]. It has been assessed by assigning a score to the known pro- and 
–anti-oxidant and summing the scores to determine the OBS. The elements that have been 
included in the scoring and the methodology used in assigning the scoring has differed from 
study to study [156, 159, 175].  
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The gaps in knowledge 
Although findings from laboratory studies and basic biology supports the association between 
OS and hypertension, results from human studies have been entirely inconsistent. The results 
from clinical studies have been driven by the type of OS biomarker used and population being 
studied [35]. Few studies have examined multiple markers of OS and hypertension among the 
same study population. To the best our knowledge, participants included in studies that have 
examined the relationship between OS and hypertension tend to be homogeneous, usually from 
same race and or ethnicity. Finally, although some studies have demonstrated the utility of OBS 
as representing the overall oxidative burden and have found the score to be associated with some 
health outcomes, to the best of our knowledge, the association between OBS and hypertension 
has not been examined.  
Research Plan 
Objectives, Specific aims and study hypotheses 
The primary objective of this dissertation is to examine the associations of stress (psychosocial 
and oxidative) with diabetes management, diabetes complication and hypertension. The 
association between OBS and hypertension will also be investigated. 
Aim 1: Using data from Kaiser Permanente Georgia (KPGA) survey on Health and Healthy 
Behaviors that has been linked to patients clinical and pharmacy information (n=537), 
investigate the association between work-related psychosocial stress and glycemic control among 
working adults with DM. I hypothesized that adults with DM who experience more strain and 
less support at the work environment will have poorer glycemic control. 
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Aim 2: Using the same KPGA data as in study aim 1 above, examine the association between 
general psychosocial stress and changes in eGFR over time among DM patients. I hypothesized 
that higher general psychosocial stress will be associated with decline in eGFR. 
Aim 3: Using data from the cross-sectional study on Race, Stress and Hypertension (SRSH), 
examine the association between oxidative stress (F2-isoP, FOP, MtDNA and g-Toc), oxidative 
balance score (OBS) and hypertension. I hypothesized that oxidative stress will be positively 
associated with hypertension while OBS will be inversely associated with hypertension. 
Methods for Aims 1 and 2 
To address the first two study questions (study aims 1 and 2), data from the 2005 Kaiser 
Permanente Georgia (KPGA) Survey on Health and Healthy Behaviors will be utilized. 
Data Source 
Sample Selection and Survey Administration 
Study participants were working adults who at the time of the data collection in 2005 met the 
following inclusion criteria: (1) age 25-59 years; (2) diagnosed with DM but without major 
micro or macrovascular complications; (3) employed by one of the 100 largest private or public 
employer groups offering KPGA as an insurance option; (4) enrolled in KPGA; and (5) 
subscribed within the enrolled family. Stratified randomized design was used to collect relatively 
well balanced samples of respondents by condition cohort and by primary care practice.  In the 
initial data collection, three conditioned cohorts were identified for sampling: adults with 
diabetes, adults with elevated lipids but no history of advanced coronary artery disease (CAD), 
and adults without any identifiable major physical or mental morbidities (i.e. "low risk" adults). 
The current study used data on only the diabetes conditioned cohorts. Only individuals who 
reported their race as African American (black) or Caucasian (white) will be included in the 
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current study because other racial/ethnic groups represented a very small proportion of KPGA 
enrollees. There were a total of 625 participants in the diabetes conditioned cohort but study 
specific sample size will vary due to different exclusionary criteria that will be implemented. The 
sample size for study 1 will be 537 and that of study 2 will be 575. KPGA Institutional Review 
Board reviewed and approved the study protocol.  
Study Variables 
Psychosocial Stress – Work environment.  Work-related stress was assessed by the 4 MIDUS 
subscales of work decision latitude (6 items), job demands (5 items), coworker support (2 items), 
and supervisor support (3 items).  Each item was assessed using a 5-response Likert scale: "All 
of the time", "Most of the time", "Sometimes", "Rarely", "Never".  Each subscale was scored 
from 0 (most strained, least supportive work climate) to 100 (least strained, most supportive 
work climate) by transforming each item response from 0-100 (and reverse coding where 
necessary). An overall work-related psychosocial stress score was computed as the mean of these 
4 subscales.   The Cronbach’s alphas for work decision authority, job demands, coworker 
support, and supervisor support subscales were 0.88, 0.78, 0.73, and 0.89, respectively – similar 
to the MIDUS subscale alphas (0.68 for work decision authority, 0.74 for job demands, 0.74 for 
coworker support, and 0.87 for supervisor support) [176].  
Psychosocial Stress- Social Settings.  This was assessed by 2, 4-item subscales of friend/family 
support and friend/family strain, which was adapted from the MIDUS survey [176].  The 
MIDUS scales for family and friends were essentially identical except for the reference (e.g. 
"How much do members of your family really care about you?" and "How much do your friends 
really care about you?"); therefore, we chose to combine the references to create a measure of 
psychosocial stress in the social climate (e.g. "How much do your friends and family members 
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really care about you?").  Like the work-related psychosocial stress, the friends/family related 
psychosocial stress was scored from 0 (most strained, least supportive social climate) to 100 
(least strained, most supportive).   
Dietary Intake. Percent calories from fat, fruit and vegetable (F/V) servings per day, and daily 
fiber intake (grams per day) were derived from responses to the Block fat and F/V screeners 
[177]. 
Leisure Physical Activity.  Leisure physical activity (LPA) was ascertained from responses to the 
Behavioral Risk Factor Surveillance Survey (BRFSS) physical activity items in the survey and 
measured using 2 dichotomous variables: physical activity at the recommended level and 
physical inactivity [178, 179]. Physical activity at the recommended level was defined as 
moderate physical activity (leisure activities of moderate intensity for a minimum of 30 minutes 
per day, 5 or more days per week) or vigorous physical activity (leisure activities of vigorous 
intensity for a minimum of 20 minutes per day, 3 or more days per week).  Physical inactivity 
was considered to be <10 minutes per week of moderate or vigorous physical activity.       
Physical and laboratory examinations.  The physical and laboratory examination measures were 
extracted from KPGA’s electronic medical record (EMR) data system.  Height and weight, 
systolic blood pressure (SBP), and diastolic blood pressure (DBP) associated with primary care 
visits were collected.  Height and weight were used to compute body mass index (BMI).  SBP 
and DBP were used to compute mean arterial pressure (MAP). Other component measures 
including HbA1c, total cholesterol, LDL, HDL and serum creatinine were obtained from 
laboratory results.   
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For each respondent, component measures were summarized into an annual measure.  If a 
respondent had more than one result for a component measure in a year, median of the results for 
the respondent in the year was retained for the component measure.  Since most respondents had 
none, one, or two results on a component measure in a year, the mean and median were 
equivalent for most respondents.   
Covariates.  Respondent-level covariates included: age group, gender, race/ethnicity, and level 
of education.  Age (25-34, 35-39, 40-44, 45-49, 50-54, 55-59), and gender were assessed from 
KPGA computerized data; race/ethnicity (African American, white, other/unknown) and level of 
formal education (high school education or less, some college, college graduate, post-graduate) 
were assessed from survey. 
Calculated Variables 
Estimate Glomerular Filtration Rate. The main dependent variable for the second study will be 
eGFR. Using the serum creatinine (SCr) measures, the annual eGFR will be estimated using the 
Modification of Diet in Renal Diseases (MDRD) equation [180]. 
 
𝒆𝑮𝑭𝑹 = 186 ∗ 𝑺𝑪𝒓−1.154 ∗ 𝑨𝒈𝒆−0.203 ∗ [1.210 𝑖𝑓 𝑏𝑙𝑎𝑐𝑘] ∗ [0.742 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒] 
 
Laboratory factor. The following baseline measures were obtained from participants’ laboratory 
records; low density lipoprotein (LDL), high density lipoprotein (HDL) and cholesterol.  Using 
the lab measures and BMI values, we will calculate a laboratory factor using principal 
component analysis to reduce the number of parameters to be estimated in the model. The 
reciprocal of HDL will be taken to make the direction of all the factors consistent before 
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performing principal component analysis. We will retain the first factor only if it explains more 
than 50% of the variance among the variables, otherwise, will retain the second factor as well. 
Dietary Intake and Physical Activity factor. We will derive the percent calories from fat, the 
number of fruit and vegetable (F/V) servings per day, and daily fiber intake (grams per day) from 
the responses to the Block F/V screener [177] from the 2005 survey. Using the Behavioral Risk 
Factor Surveillance Survey (BRFSS) physical activity items, we will categorize participants as 
meeting the physical activity as recommended by the CDC [178, 179]. Using a principal 
component analysis, we will create a dietary and physical activity factor using the dietary and 
physical activity variables to reduce the number of parameters to be estimated in the model. We 
will retain the first factor only if it explains more than 50% of the variance among the variables, 
otherwise, will retain the second factor as well. 
Neighborhood-based Socio-economic status (SES) index.  Individual level SES were generally 
not available so will not include in this study as a covariate, rather we will use the neighborhood-
based SES, a validated scale comprising of  7 measures from the US Census at the census track 
level [181]. 
Use of insulin and oral hypoglycemic agents. A binary variable will be created to indicate insulin 
use versus insulin non-use. For individuals using oral hypoglycemic (OH) agents, we will 
estimate the proportion of days with OH coverage in 2005.  
 
Data Analyses Plan 
The study aim #1 will be addressed using linear regression model (PROC REG procedure) and 
individual growth model approach (PROC MIXED procedure) in SAS [182]  to examine the 
relationship between work-related psychosocial stress and glycemic control. The linear 
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regression model will be used to assess the relationship between HbA1c and work-related 
psychosocial stress sub-scales and their two-way interactions at study baseline (2005). The linear 
growth model will be used to examine the relationship between work-related psychosocial stress 
in 2005 and HbA1c measures from 2005 to 2009 while centering time at 2005. Different 
covariance matrices will be explored to identify the matrix that best fit the data. Both the linear 
and the growth model will be fit in a hierarchical fashion: model #1 will not include any 
covariate; model #2 will adjust for socio-demographic variables (age, sex, race/ethnicity, 
neighborhood-based SES, marital status and education level); model #3 will adjust for the diet 
and physical activity factor; model #4 will adjust for the laboratory factor, MAP, insulin use and 
proportions of days covered by oral hypoglycemic agents in 2005. Statistical significance for all 
analyses will be determined at p<0.05. 
The study aim #2 will be addressed using a confirmatory factor analysis (CFA) and a linear 
growth model in a structural equation model (SEM) framework. Latent psychosocial stress 
variable will be specified using CFA by loading the four work-related psychosocial stress 
indictors and the social environment stress indicator on the latent stress variable. Without an a 
priori hypothesis about the functional form of the relationship between stress and eGFR over 
time, in the final conditional growth model, stress will be specified with direct effects on the 
repeated measures to allow the greatest flexibility to obtain a time-varying effect estimates. In 
the final growth model, we will controll for the annual HbA1c measures as a time varying 
covariate while socio-demographic variables (sex, age, race, education, neighborhood-based 
SES), smoking, BMI, insulin use, medication coverage (proportion of days covered by oral 
hypoglycemic agents), and MAP will be controlled for as time invariant covariates. The robust 
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maximum likelihood estimator will be used. Statistical significance will be determined at a two 
sided alpha level of 0.05. 
 
Methods for Study Aim 3 
Data Source 
To address study aim #3, data from the Study on Stress, Race and Hypertension (SRSH) will be 
used. SRSH was designed to assess dietary, lifestyle and psychosocial exposures, in relation to 
blood pressure and presence of arterial hypertension in three groups of subjects:  Caucasians, 
African-Americans and West African immigrants. The study included individuals aged 25-74 
years who self-identified as Non-Hispanic Whites (NHW), African Americans (AA) or West 
African Immigrants (WAI) and who were residents of Georgia. NHW and AA subjects were 
selected from among 800 participants in a previously completed feasibility phase of the Georgia 
Cohort Study (GCS). The WAI subjects were recruited de novo using previously established ties 
with Atlanta churches that included large proportions of WAI. The sample of GCS participants 
was selected after the completion of the WAI recruitment and frequency matched to WAI 
participants on age and sex. All study protocols were reviewed and approved by the Institutional 
Review Boards of the Emory University and the Georgia State University. 
Variables and Measures 
Blood Samples 
All participants provided blood samples that were drawn into five 10mL vacutainer tubes (2 
sodium heparin tubes, 1 EDTA tube, and 2 red top tubes for serum collection) and immediately 
plunged into ice and protected from direct light.  Plasma, serum, and buffy coat specimens were 
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separated within 4-8 hours by centrifugation under refrigeration, aliquoted, frozen and stored at -
80°C.  The aliquots were then shipped overnight on dry ice for molecular analysis by the 
Molecular Epidemiology and Biomarker Research Laboratory (MEBRL) at the University of 
Minnesota, Minneapolis, MN.   
Laboratory Analysis 
Plasma lycopene, α-carotene, β-carotene, β-cryptoxanthin, zeaxanthin, lutein, α-tocopherol, and 
γ-tocopherol were measured by a high performance liquid chromatography (HPLC) assay using 
previously described methods [183-185].  Serum ferritin was measured by an antibody-based 
method using Roche 911 analyzer.  
F2-Isoprostanes (F2-isoP). Gas chromatography-mass spectrometry (GCMS) [161], a gold 
standard for the measurement of F2-isoP, was used to measure plasma free F2-isoP. The F2-isoP 
were extracted from the plasma sample with deuterium (4)-labeled 8-iso-prostaglandin F2 alpha 
as an internal standard. Unlabeled, purified F2-sioP was used as a calibration standard. 
Fluorescent Oxidative Products (FOP). The measurement of FOP was performed using a 
modified Shimasaki  method [186], which has been previously described elsewhere [187].  A 
mixed solution was centrifuged for 10mins at 3000rpm, 1mL of supernatant was added to 
cuvettes for spectrofluorometric readings, and a relative fluorescence intensity unit per milliliter 
of plasma was estimated using the spectrofluorometer [187]. Calibration was performed using 
standard quinine diluted in 0.1 NH2SO4.  
The copy number of mitochondrial DNA (MtDNA). MtDNA was determined using real-time 
quantitative PCR described by Shen et al [188].  Two primers, one for MtDNA and the other for 
DNA were used in the two steps of relative quantification for MtDNA content:  one for the 
amplification of the MT-ND1 gene in MtDNA, and another for the amplification of the single-
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copy nuclear gene human globulin (HGB). The ratio of MtDNA and nuclear DNA was 
determined using serially diluted genomic sample DNA of a healthy referent [188]. 
Oxidative Balance Score (OBS) 
The OBS will be estimated using a priori selected 13 pro- and anti-oxidants components 
according to our previous study [175] and those of others [189, 190] as listed in Table 1.1. The 
score will combine plasma micronutrient measurements and lifestyle behaviors. The plasma level 
of pro- and anti-oxidants, will be divided into sex and race/origin specific tertiles. The number of 
minutes of physical activity per week will also be divided into tertile. For anti-oxidants (α-
carotene, β-carotene, β-cryptoxanthin, zeaxanthin, lutein, α–tocopherol) and physical activity, the 
first to third tertiles will be assigned scores of 0-2. For pro-oxidants (ferritin), the first to third 
tertile will be assigned a score of 2-0 respectively. To maintain scoring consistency, we will 
assign a scores of 0-2 to the other categorical OBS components. We will assign a score of 0-2 for 
obese (BMI ≥30kg/m2), overweight (BMI=25-29.99kg/m2) and normal weight (BMI <25kg/m2) 
respectively. For smoking or alcohol use: never-smokers or never-drinkers will receive a score of 
two; former smokers and former drinkers or those with missing information a score of one; and 
current smokers and current drinkers a score of zero.  For NSAIDs and aspirin, zero points will 
be assigned to participants reporting no regular use of these medications, one point to those 
reporting no usage or missing information, and two points to those reporting regular use.   The 
points assigned to each component will be summed up to represent the overall OBS. OBS will 
then be categorized into three approximately equal intervals; 3-10, 11-17 and 18-25 to represent 
low, medium and high OBS, respectively. OBS will be used in a separate analysis as a 
continuous variable. 
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Table 1.1. OBS Assignment 
Component Score Assignment 
Plasma Zeaxanthin 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Plasma Cryptoxanthin 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Plasma Lycopene 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Plasma α-carotene 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Plasma β-carotene 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Plasma α-tocopherol 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Serum Ferritin 2=low (1st tertile), 1=medium (2nd tertile), 0=high (3rd tertile) 
Physical Activity 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Alcohol use 0=current drinker, 1=former drinker/missing, 2=never drinker 
Smoking 0=current smoker, 1=former smoker/missing, 2=never smoked 
Aspirin use 0=no regular user, 1=unknown/missing, 2=regular user 
NSAID use 0=no regular user, 1=unknown/missing, 2=regular user 
Obesity 0=obese,  1=overweight, 2=normal weight 
NSAID = Non-steroidal anti-inflammatory drugs. Normal weight=BMI<25kg/m2, 
overweight=BMI between 25.0-29.9kg/m2, Obese=BMI ≥30kg/m2.  
 
Blood Pressure and Hypertension 
Trained and certified staff took all blood pressure measurements. After participants had rested 
about five minutes seated, three blood pressure measures were taken with at least a minute 
interval using mercury sphygmomanometry and appropriately sized arm cuffs. The mean of the 
three blood pressure measures will be estimated and used in this study. Systolic and diastolic 
blood pressure (SBP and DBP) measures will be expressed as a separate continuous variables.  
Individuals will be considered hypertensive if they meet any of the following conditions; (a) ever 
been told by a health care professional that s/he has hypertension, (b) on a blood pressure 
lowering medications, (c) had systolic blood pressure (SBP) equal or greater than 140mmHg (c) 
had diastolic blood pressure (DBP) equal or greater than 90mmHg.  
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Statistical Analysis 
All analyses will be performed using SAS version 9.3 [182].The F2-isoP, FOP, MtDNA and γ-
Toc will each be dichotomized into a ‘low’ and ‘high’ using their respective sex and race/origin 
specific median as the cut-off. SBP and DBP will be modeled as continuous variables. 
Hypertension will be included as a dichotomized (hypertensive and normotensive). OBS will be 
used both as a continuous and a three level categorical variable.  
The first series of statistical analyses will examine the association between SBP, DBP and each 
of the OS markers and OBS entering them as continuous variables in a linear regression. The 
second set of analyses, will examine the association of hypertension with OBS and with each 
biomarker of OS. The odds ratios (OR) for the continuous OS variables in the logistic equation 
will be scaled to their respective one standard deviation. Except for associations involving OBS, 
each linear and logistic regression analysis will adjust for race/origin, age, sex, education and 
BMI. Analyses involving OBS will not control for BMI because it was included in the scoring. 
To estimate the effect of missing data, a sensitivity analysis will be performed by imputing the 
missing values in two different fashions: 1) using five times multiple imputation method 
available in SAS and 2) by replacing missing values with sex and race specific mean. All 
measures of association will be accompanied by 95% confidence intervals (CI).  Statistical 
significance will be determined at two sided p-value of <0.05. 
Significant and impact of the study 
The purpose of the current study will be to address several of the gaps identified in the literature 
with respect to psychosocial stress and DM. This study is important because the findings from 
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previous studies have been inconsistent, inundated with small sample sizes, the use of general 
measures of psychosocial stress and  difficulty measuring the stress concept.  
The innovative feature of the current study is the use of a unique study population, longitudinal 
data, and the use of latent analysis approach. To the best of my knowledge, this is the first study 
to investigate the association between psychosocial stress at the work environments and 
glycemic control among working adults with DM who had no major DM related complications. 
The sample size of the study sample is also adequate. Another strength of the study is the use of 
confirmatory factor analyses in the measurement and quantification of psychosocial stress which 
will explicitly account for differential measurement error related to the different stress sub-
scales, thus, yielding a more accurate and precise assessment of the underlying psychosocial 
stress construct.   
In relation to OS, OBS and hypertension, although, basic biology and some observational studies 
have found association between OS and hypertension, the use of anti-oxidants supplementation 
to reduce blood pressure have not yielded expected results. Part of the reasons for the 
inconsistencies between anti-oxidants supplementation and blood pressure reduction identified 
include: 1) the trial designs; 2) patients cohorts; 3) type of anti-oxidants; 4) and the dosage of 
anti-oxidants. To overcome the problem of using one OS exposure variable at a time, the use of 
OBS has been proposed but its use has been limited to cancer research.  The current study will 
examine the association between OBS and hypertension using plasma levels of micro-nutrients 
which may accurately represent current intake and availability of pro- and anti-oxidants 
compared to food frequency questionnaire-derived measures. Another important methodological 
feature of the present study will be the use of a racially and ethnically diverse population.  This 
will allow for assessing multiple biomarkers of OS and their relation to each other and to 
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hypertension in US born whites and blacks and in West African immigrants.  One of the 
limitations of OS and hypertension research is that study findings have been driven by the 
population being study and the type of OS marker used. Therefore our use of racially ethnically 
diverse population while utilizing multiple markers of OS makes this study a unique. 
The results of this study will help direct future epidemiologic studies that will examine the 
association between psychosocial stress and DM, particularly, by identifying the best statistical 
methods to use to combine psychosocial stress from multiple sources so as to control for 
measurement errors. Secondly, the results from the association between OS, OBS and 
hypertension will help re-direct the research in this area as few studies on the topic exixts. 
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Abstract 
Objective: To examine the association between work-related psychosocial stress and glycemic 
control among patients with diabetes mellitus at both study baseline and over time.  
Materials and Methods: We used data from Kaiser Permanente Georgia (KPGA) 2005 survey 
on Health and Healthy Behaviors linked with patients’ clinical, pharmacy and laboratory records 
for the period 2005-2009. Study participants (n=537) consisted of working adults aged 25-59 
years, diagnosed with diabetes mellitus (DM) but without advanced micro or macrovascular 
complications at the time of the survey. Four work-related psychosocial stress sub-scales were 
used for the study. We estimated the baseline (2005) association between each work-related 
psychosocial stress sub-scales as well as their two way interactions and HbA1c in linear 
regression analyses. Using individual growth model approach, we estimated the association 
between each work-related psychosocial stress subscale and HbA1c over time. Each model 
controlled for socio-demographic variables, diet and physical activity factors, laboratory factors, 
physical examinations variables and medication use in a hierarchical fashion. 
Results: After adjusting for all study covariates, we did not find a significant association 
between work-related psychosocial stress and glycemic control either at baseline or over time. 
Conclusion: Among fairly healthy middle aged working adults with DM, psychosocial stress at 
the work environment was not directly associated with glycemic control.  
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Introduction 
Diabetes mellitus (DM) is a major public health problem. It significantly increases the risk of 
micro-vascular complications such as retinopathy, nephropathy and neuropathy, and macro-
vascular damages including myocardial infarction and stroke [86, 191, 192].  Currently, an 
estimated 8.3% American adults have overt DM while about 35% have pre-diabetes [12]. In the 
past three decades, DM prevalence has more than doubled and related complications have 
significantly increased [22-24]. Although a strong connection exists between genetic factors and 
DM etiology [14-16], recent increase in DM prevalence and its related complications have 
mostly been attributed to internal environmental factors such as stress [20, 21] and the external 
environmental factors such as diet and sedentary behaviors [17-19]. Long term complications 
from DM are primarily the results of chronic elevation and/or fluctuations of blood glucose level, 
which in turn damage blood vessels resulting in micro and macro-vascular complications [193, 
194]. With increasing life expectancy but reduced age of DM onset in the US [13], the 
importance of good glycemic control to prevent and or delay the onset and progression of long 
term DM related complications cannot be overemphasized.  
Proper DM management is demanding and involves adherence to multiple activities including 
diet, physical activity, medication use, and self-monitoring of blood glucose level [195]. Each of 
these activities is affected by multiple factors including: socio-demographic characteristics such 
as age, race, and socio-economic status [196, 197]; the presence of other chronic conditions such 
as obesity and hypertension [198]; and psychosocial stress [92, 199].  
The relationship between general measures of psychosocial stress and glycemic control is well 
established [77, 200-203]. Laboratory studies have demonstrated that stressful situations such as 
unpleasant interviews or impending examinations destabilized blood glucose levels [91, 204]. 
Studies in real life settings, including meta-analysis corroborated the initial laboratory findings 
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[22, 23, 77, 92, 93, 199, 201]. Although the exact mechanism through which psychosocial stress 
may impact diabetes management is not very well understood, the underlying pathway has been 
hypothesized to involve physiological and/or behavioral mechanisms [77, 78, 81, 205]. 
Physiologically, psychosocial stress has been proposed to impact glycemic control through series 
of processes involving the hypothalamic-pituitary-adrenal axis (HPA) that leads to accumulation 
of visceral fat due to altered energy homeostasis and increased insulin resistance due to 
persistently higher levels of cortisol [78, 206]. The HPA is the major controller of hormones 
involved in the regulation of peripheral insulin sensitivity [207]. The behavioral aspect comes 
from increased engagement in risky lifestyle behaviors (such as smoking, excessive alcohol use), 
decreased capacity to make modifications to lifestyle behaviors (such as healthy eating and 
physical activity), medication adherence and difficulties in self-care among individuals with 
higher levels of psychosocial stress [82, 83, 205, 208].  
Despite several studies investigating the relationship between general measures of psychosocial 
stress and glycemic control, limited studies have examined this association using psychosocial 
stress from a specific source, particularly at the work environment. Work-related psychosocial 
stress has been associated with general ill health [209, 210]. The job strain model has been used 
to explain the association. Individuals working in jobs that have high demand and low control are 
at greater risk of stress-related ill health and diseases [95]. The American Institute of Stress has 
noted that job stress is by far the major source of stress among American adults [211]. A report 
by the National Institute for Occupational Safety and Health (NIOSH) included a finding from a 
prior study that noted that stress at the work environment is strongly associated with health 
complaints than any other life stressors [212]. Spending eight or more hours a day and five or 
more days a week, several American adults spend more time at the work environment than they 
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do with family and friends. It is therefore important to understand stress at the work environment 
and how it relates to health, particularly, DM and its management. Research on stress at the work 
environment and glycemic control appears to be limited to the work by Trief and colleagues [95]. 
Trief et al study did not find a significant association between psychosocial stress at the 
workplace and glycemic control [95]. The current study was therefore designed to further 
examine the relationship between work-related psychosocial stress and glycemic control while 
addressing the limitations of the unique study; cross-sectional study design, small sample size, 
and inclusion of only insulin requiring DM patients. Given that 64.5% of American adults are in 
the work force [213], 8.3% diabetes prevalence [12], and the work environment has an impact on 
overall health, we conducted a study of both cross-sectional and longitudinal analyses of the 
association between work related psychosocial stress and glycemic control. The study had two 
objectives: (1) to examine the association between four sub-scales of work-related psychosocial 
stress as well as their two-way interactions and HbA1c at study baseline, and (2) to examine the 
association between four work-related psychosocial stress subscales and glycemic control over 
time; while adjusting for socio-demographic variables, diet and physical activity factor, 
laboratory and physical examinations variables and medication use in a hierarchical fashion. 
 
Methods 
Study population 
We utilized data from Kaiser Permanente Georgia (KPGA) 2005 Survey on Health and Healthy 
Behaviors. Study participants consisted of working adults who at the time of the data collection 
in 2005 met the following inclusion criteria: (1) aged 25-59 years; (2) diagnosed with diabetes 
but without advanced micro or macrovascular complications; (3) employed by one of the 100 
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largest private or public employer groups offering KPGA as an insurance option; (4) enrollee of 
KPGA; and (5) subscriber within the enrolled family. Only individuals who reported their race as 
African American (black) or white were included in the current study due to the small sample 
size of other racial groups. KPGA IRB reviewed and approved the study protocol. 
 
Data and Measures 
The survey instrument included items and scales that had previously been used in other studies 
and which had demonstrated reliability and validity [176, 181]. Data obtained from the 
participants’ survey was linked to their clinical information including pharmacy and laboratory 
records from 2005 through 2009.  
The dependent Variable: The dependent variable was glycemic control assessed using HbA1c 
measures from participants’ laboratory results from 2005 through to 2009. HbA1c measures 
within a calendar year were summarized into an annual measure and where a respondent had 
more than one result within a calendar year, the median was retained.  Since most respondents 
had one or two results on HbA1c per year, the mean and median were equivalent for most 
respondents.  
The main independent variable: The main independent variable was work-related psychosocial 
stress. This was assessed using 4 stress subscales from the Midlife in the United States (MIDUS) 
study [176]; work decision authority (6 items), job demands (5 items), coworker support (2 
items), and supervisor support (3 items).  Each item was assessed using a 5-response Likert 
scale: "All of the time", "Most of the time", "Sometimes", "Rarely", "Never".  Each subscale was 
scored from 0 (most strained, least supportive work climate) to 100 (least strained, most 
supportive work climate) by transforming each item response from 0-100 (and reverse coding 
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where necessary).  An overall work-related psychosocial stress score was computed as the mean 
of the 4 subscales.  The Cronbach’s alpha for the decision authority, job demands, coworker 
support and supervisor support subscales were 0.88, 0.78, 0.73, and 0.89 respectively. 
Covariates: 
Physical Examinations: Data on height, weight, systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) were obtained from medical records associated with participants’ primary 
care visits. Height and weight were used to compute body mass index (BMI). SBP and DBP 
were used to compute mean arterial pressure (MAP).  
Laboratory factor: The following baseline measures were obtained from participants’ laboratory 
records; low density lipoprotein (LDL), high density lipoprotein (HDL) and cholesterol.  Using 
the lab measures and BMI values, we created a laboratory factor using principal component 
analysis to reduce the number of parameters to be estimated in the model. The reciprocal of HDL 
was taken to make the direction of all the factors consistent before performing principal 
component analysis. We retained the first factor which explained more than 50% the variance 
among the variables.  
Dietary Intake and Physical Activity factor: Percent calories from fat, the number of fruit and 
vegetable (F/V) servings per day, and daily fiber intake (grams per day) were derived from 
responses to the Block F/V screener [177] from the 2005 survey. Using the Behavioral Risk 
Factor Surveillance Survey (BRFSS) physical activity items, we assessed physical activity at the 
recommended level [178, 179]. Recommended physical activity level was defined as moderate 
physical activity (leisure activities of moderate intensity for a minimum of 30 minutes per day, 5 
or more days per week) or vigorous physical activity (leisure activities of vigorous intensity for a 
minimum of 20 minutes per day, 3 or more days per week).  Using principal component analysis, 
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we created dietary and physical activity factor using the dietary and physical activity variables to 
reduce the number of parameters to be estimated in the model. A single factor that explained 
more than half the variance among the variables was retained and included in the model. 
Neighborhood-based Socio-economic status (SES) index: Individual level SES were generally 
not available so we did not include in this study as a covariate, rather we used the neighborhood-
based SES, a validated scale comprising of  7 measures from the US Census at the census track 
level [181]. 
Use of insulin and oral hypoglycemic agents: A variable was created for insulin use (1=use 
insulin, 0=not using insulin). For individuals using oral hypoglycemic (OH) agents, we estimated 
the proportion of days with OH coverage in 2005.  
Other Socio-demographic measures: Participants age (in years) and sex (males, female) were 
assessed from the KPGA computerized data. Race/ethnicity (Caucasian (white), African 
American (black)), level of formal education (high school education or less, some college, 
college graduate, post-graduate), and marital status (married and not married) were assessed 
from the survey. 
Statistical analysis 
We addressed the first study objective using a linear regression model in SAS software version 
9.3 [182] to assess the relationship between HbA1c and work-related psychosocial stress sub-
scales and their two-way interactions at study baseline (2005). We fit four regression models for 
each of the work-related psychosocial stress subscales and their two way interactions in a 
hierarchical fashion: model 1 did not include any covariate; model 2 adjusted for socio-
demographic variables (age, sex, race/ethnicity, neighborhood-based SES, marital status and 
education level); model 3 adjusted for the diet and physical activity factor; model 4 adjusted for 
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the laboratory factor, MAP, insulin use and proportions of days covered by oral hypoglycemic 
agents in 2005.  
The second study objective was addressed using the individual growth model approach in SAS 
using the PROC MIXED procedure [182]  to examine the relationship between work-related 
psychosocial stress and in 2005 and HbA1c from 2005 to 2009. Time from 2005-2009 was 
measured as 0-4 respectively in the model. We used the unstructured variance covariance matrix 
for the intercepts and the slopes in the mixed model. Like the first study objective, we fit four 
hierarchical models entering the variables in the same order as the linear regression models. 
Statistical significance for all analyses was determined at p<0.05. We hypothesized a significant 
association between HbA1c and the four sub-scales of work-related psychosocial stress as well 
as their two way interactions at baseline. We also hypothesized that higher work-related 
psychosocial stress at baseline would be associated with poor glycemic control over time.  
 
Results 
Characteristics of Study Population 
Overall, 652 participants met the original study inclusion criteria. We excluded 115 (17.6%) 
individuals who had no measure for HbA1c in any year from 2005-2009, bringing the sample 
size to 537. Of this, 58% were females (Table 1). Age ranged between 27 and 59 years with 
mean age of 49.7 (SD= 6.9) years. About 55% were blacks, the vast majority (76%) had some 
college education or were college graduates and about 60% were married or with a partner. 
Approximately 23% of participants were on insulin while the remaining were using other types 
of diabetes management regimen including OH agents. Those on OH agents had average 
coverage of 75.3% of the days in 2005.  At the baseline in 2005, the mean HbA1C of the 
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participants was 8.1% SD=1.8). HbA1c values were relatively constant between 2005 and 2009 
with mean annual values ranging between 7.9 and 8.1% (Table 2). The mean score for work-
related psychosocial stress subscales ranged between 47.1 (work demands) and 63.1 (supervisor 
support). The mean BMI, HDL, LDL, MAP and cholesterol for participants at baseline were 34.3 
(SD=7.3), 48.0 (SD=13.0), 113.7 (SD=36.1), 115.0 (SD=13.4), and 188.7 (SD=41.1) 
respectively. At baseline, 65% of participants were meeting the CDC fruits and vegetable 
consumption recommendation (of five or more servings per day). Participants mean fiber 
consumption in grams per day at baseline was 20.8 (SD=5.2) while the percent calories obtained 
from fat averaged about 44.2% (SD=5.2) (Table 2). 
Results from cross-sectional analysis 
In the series of linear regression analyses for the cross-sectional data, none of the work-related 
psychosocial stress sub-scale or the overall score was significantly associated with the baseline 
HbA1c level after adjusting for socio-demographic variables and other covariates in the models. 
Despite the non-significant relationship between the individual sub-scales and HbA1c, we tested 
for the two way interaction between the subscales and their relationship with HbA1c. This 
approach was taken due to the job strain model which suggests interaction between job demand 
and decision control. We found the interaction between job demand and supervisor support to be 
marginally significant with HbA1c in the crude model (model 1) but significance disappeared 
after adjusting for the study covariates. None of the other interaction terms was significant either 
in the crude model or in the adjusted models (Table 3). 
 
Results from Mixed Models 
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In the unconditional mixed model, we found the mean HbA1c value at baseline to be 8.0%.  
Although not statistically significant, there was a marginal decline in HbA1c value at an average 
of 0.022% per year during 2005-2009. In the set of the mixed models, we examined the 
relationship between the baseline measures of each of the four subscales of work-related 
psychosocial stress, the overall score and HbA1c over time. None of the subscales or the overall 
score was significantly related to glycemic control over time after adjusting for socio-
demographic factors, diet and physical activity factor, laboratory factor, MAP, insulin use and 
proportions of days covered by oral hypoglycemic agents.  
Although there was no significant association between work-related psychosocial stress and 
glycemic control, four of the covariates were significantly associated with HbA1c; race, insulin 
use, percent oral hypoglycemic coverage and laboratory factor. On average, blacks had 
significantly higher mean HbA1c at baseline than whites (0.7%, p=0.001), and insulin users had 
significantly higher HbA1c than non-insulin users (1.0%, p<0.001) at baseline. At baseline, 
increasing oral hypoglycemic coverage was significantly associated with lower HbA1c (-1.5%, 
p=0.001) and a unit increase in the laboratory factor was associated with 0.3% increase in 
HbA1c (p=0.004).   
Discussion 
In the current study of relatively large sample (N=537) of adults with DM, who were using 
different DM management regimen, we aimed to examine the relationship between HbA1c and 
work-related psychosocial stress sub-scales as well as the overall score at baseline in two 
different set of analyses - cross-sectional and longitudinal. The focus of the study was to examine 
whether or not stress at the work environment was significantly associated with glycemic control 
among working adults with DM. The results from the analyses did not support either of our 
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hypotheses. We did not find a significant association between any of the baseline measures of 
work-related psychosocial stress sub-scales or the overall score and glycemic control at baseline 
or over time among study participants. However, in an uncontrolled model, we found an 
interaction between job demand and supervisor support subscales to be significantly associated 
with HbA1c. The interaction term suggested that job demand was related to HbA1c conditioned 
on the level of supervisor support. This finding warrants further research.  
The finding from the current study is consistent with that of Trief and colleagues[95] in specific 
and other studies that have examined the association between work-related psychosocial stress 
and DM in general [214-216]. While Trief’s study included only insulin requiring DM patients, 
the current study included patients that were using different diabetes management approach 
including OH agents, yet both studies arrived at similar conclusions.  
General measures of psychosocial stress have mostly been associated with DM onset and 
management [93, 217]. The results have, however, been unclear for the association between 
work-related psychosocial stress and diabetes (incidence or control). It appears stress at the work 
environment has very limited relationship with DM in general. For instance, a large French study 
did not find work-related psychosocial stress (psychosocial demands, decision latitude and social 
support) to be associated with DM incidence [215]. Similarly, a Canadian study did not find a 
significant association between any of the sub-scales of psychosocial stress at the work 
environment and incident DM among men, although in women, low levels of job control was 
associated with increased risk of DM incidence [214]. A meta-analysis of nine studies concluded 
‘the evidence does not support the hypothesis that work-related psychosocial stress increases the 
risk for DM’ [216].  
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Although our study findings are consistent with the other prior study, our study population may 
be different from the general DM patients and may partly explain the recent findings. First our 
study population was young, aged 25-59 years without advanced micro or macrovascular 
complications at the time of the survey. Secondly, participants were insured within KPGA 
system, an integrated delivery system of well-established DM management program [218]. 
Access and coverage for DM management may be better in the study population than the general 
diabetes population, thus, work-related psychosocial stress as an isolated factor might not 
significantly impact glycemic control among this group. For instance, less than a quarter of the 
study participants were on insulin and those on OH agents had an average coverage of 75.3% of 
the days in 2005. The percent medication coverage may even be higher considering the fact that 
some individuals may have filled their prescriptions outside the KPGA system and may not have 
been captured by the study as filling their prescription. Although not statistically significant, we 
observed HbA1c decline among study population during the period under consideration, an 
indication this population may be different than the general DM population.  
The limitations of the current study need to be noted. First, we did not have information on two 
important covariates; occupation information and length of time since participants have had DM. 
Although stress is highly personalized and its perception can vary depending on personality type, 
interpretation of life events and cultural context [84], the nature of some occupations may be 
more stressful than others.  Similarly, length of time since DM onset has been directly related to 
glycemic control [219] so we recognize the need to have included these two variables but they 
were not available. Secondly, participants were enrollees of KPGA and results may not be 
generalizable to uninsured patients, those in other health insurance system or patients in other 
geographic locations.  
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Conclusion 
The current study did not find a direct significant association between HbA1c and any of the 
work-related psychosocial stress sub-scale or the overall score after adjusting for study 
covariates. The study finding is consistent with a prior study by Trief and colleagues. Since only 
two studies have been conducted in this area, although, each with a unique study population, 
more studies need to focus on this topic. 
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Tables and figures 
Table 2.1 Demographic Characteristics of Study Population 
Demographic Variable  Percent (n) 
Age (Years) - 2005 49.7(7.0)* 
Sex 
    Male 42.5% (228) 
   Female 57.5% (309) 
Race 
    White 44.9% (241) 
   Black 55.1% (296) 
Education 
    Less than HS 4.8 % (26) 
   HS Grad 19.2% (103) 
   Some College 36.3% (195) 
   College Grad 39.7% (213) 
Marital Status 
    Married 59.4% (319) 
   Not Married 40.6% (218) 
Area based SES Quartiles 
   1st Quartile 31.3% (169) 
   2nd Quartile 25.4% (136) 
   3rd Quartile 23.6% (126) 
   4th Quartile 19.4% (104) 
*Mean and standard deviation 
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Table 2.2: Distribution of Study Variables among Study Participants 
Variable Mean (SD) 
Work-Related Stress (2005) 
    Overall  Score 57.5 (14.8) 
   Decision latitude 59.2 (24.3) 
   Work demands 47.4 (18.4) 
   Coworker Support 60.3 (22.2) 
   Supervisor Support 63.2 (24.3) 
HbA1c Measures 
    Year 2005 8.1 (1.8) 
   Year 2006 8.0 (1.9) 
   Year 2007 7.9 (1.7) 
   Year 2008 8.0 (1.7) 
   Year 2009 7.9 (1.5) 
BMI (2005) 34.3 (7.4) 
HDL (2005) 48.0 (13.0) 
LDL (2005) 113.7 (36.1) 
MAP(2005) 115.0 (13,4) 
Cholesterol (2005) 188.7 (41.1) 
Fiber Consumption per day(grams) 20.8 (5.2) 
Percent Calories obtained from fat 44.2 (5.2) 
Proportion of days covered by oral agents in 2005 0.75 (0.26) 
Physical activity recommendation 35% 
Fruit/vegetable consumption recommendation 65% 
Percent on insulin 23% 
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Table 2.3: Covariates with Significant Association with HbA1c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Estimate P-Value 
Race   
   White (0), Black (1) 0.7 0.001 
Insulin Use   
   No (0), Yes (1) 1.0 <0.001 
Laboratory Measures   
   Continuous 0.3 0.004 
Oral Hypoglycemic Coverage   
   Continuous -1.5 0.001 
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Abstract 
 
Background: Psychosocial stress has been hypothesized to impact renal changes but this 
hypothesis has not been adequately tested. The aim of this study was therefore to examine the 
relationship between psychosocial stress and estimated glomerular filtration rate (eGFR) and to 
examine other predictors of eGFR changes among persons with diabetes mellitus (DM). 
Materials and Methods: We used data from Kaiser Permanente Georgia (KPGA) 2005 survey 
on Health and Healthy Behaviors linked to patients clinical and pharmacy records (n=575) from 
2005-2008. Study participants were working adults aged 25-59 years, diagnosed with DM but 
without advanced micro or macrovascular complications at the time of the survey. eGFR was 
estimated using the Modification of Diet in Renal Disease equation. A latent psychosocial stress 
variable was created from four work-related psychosocial stress subscales and a social stress 
subscale. Using a growth factor approach in structural equation model framework, we estimated 
the association between psychosocial stress and eGFR. In the final model, we controlled for 
socio-demographic variables, HbA1c, smoking, BMI, insulin use, and diabetes medication 
coverage.  
Results: The psychosocial stress variable was not directly associated with eGFR after adjusting 
for study covariates. Factors found to be associated with eGFR were age, race, insulin use and 
mean arterial pressure. The model indices suggested adequate model fit.  
Conclusion: Among DM patients with no major micro- or macro-vascular complications, we did 
not find an evidence of a direct association between psychosocial stress and eGFR after 
controlling for covariates. Predictors of eGFR changes included age, race, insulin use, and mean 
arterial pressure. 
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Background 
 
Reduced renal function, which may progress to diabetes nephropathy (DN), is a major cause of 
mortality among diabetes mellitus (DM) patients [220, 221]. It is estimated that mortality rate 
among type 1 DM patients without kidney disease approaches individuals free of the condition 
[222]. Between a quarter and a third of individuals with DM may develop DN, usually as a result 
of decline in renal function [85, 223, 224]. It is therefore crucial to understand the predictors of 
renal decline in order to minimize their occurrence and ultimately, reduce chronic kidney 
diseases (CKD) among individuals with DM.  
Among DM patients, tight glycemic control decreases the risk of renal decline and slows the 
progression of DN [86, 193]. However, some DM patients with poor glycemic control never 
develop DN while some with good glycemic control progresses to DN [85]. Such occurrence 
demonstrates that factors other than glycemic control may be important for renal decline and 
subsequent progression to DN. One obvious candidate has been genetic factors since there is a 
strong familial risk for DN; however, there has been a limited success in identifying specific 
genes that account for such predisposition among large DM population [98, 99]. Other traditional 
risk factors identified to influence the initiation, sustenance, and progression of DN include high 
blood pressure and smoking [100-102]. Hypertension, for instance, is estimated to be present in 
about 80% of patients with kidney diseases [225].  However, the variability in the onset and 
progression of DN have not been fully explained as a function of the group differences in these 
traditional risk factors alone – glycemic control, high blood pressure, and smoking [85].  In 
search for other factors to explain this variability, some non-traditional risk factors have been 
proposed to influence the renal decline in the general population, including psychosocial stress, 
oxidative stress, advanced glycation end products and activation of protein kinase C [226-228]. 
  
54 
 
The relationship between psychosocial stress and renal decline among DM patients has not been 
adequately investigated; thus, the reason for the current study.  
Psychosocial stress, defined as demanding conditions that exceed the behavioral resources of an 
individual [229] has been suspected as a potential factor in renal decline due to its established 
relationship with glycemic control, hypertension, and smoking [200, 230-232].  Another 
proposed link between psychosocial stress and renal decline is through the increased engagement 
in behaviors that may increase the risk of renal damage such as alcohol abuse, smoking and drug 
abuse [81, 105, 106, 226]. Although higher levels of psychosocial stress has been associated with 
overall poor health, high blood pressure, poor glycemic control, and smoking [22, 230, 233-236], 
the direct association between psychosocial stress and decline in renal function has not been 
adequately examined. Part of the reason for the limited research in this area is the difficulty in 
operationalizing the concept of stress. Psychosocial stress is broad and may originate from 
multiple sources such as constant exposure to socio-economically challenging environments, 
social relationships, and work environment [237-239], presenting challenges to comprehensively 
assess psychosocial stress and appropriately combining the stress subscales from multiple 
sources.  
The primary aim of the current study is therefore to examine the direct relationship between 
psychosocial stress and renal function over time among individuals with DM. Although factors 
including glycemic control, blood pressure, smoking and other socio-demographic factors have 
been associated with renal decline, the course of eGFR among DM patients can be complex and 
heterogeneous, and may be affected by multiple factors including existing comorbid conditions 
[240]. For instance, albuminuria was identified as the strongest predictor of eGFR decline among 
Caucasians with DM [241], while among Japanese with DM, higher glycemic levels was the 
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strongest predictor of eGFR decline [242]. In the light of the variability in eGFR trajectory 
among different study population, our secondary study aim was to explore other documented 
predictors of renal decline among this unique study population (White and Black working adults 
with DM but without a major micro- or macro-vascular complications). In this study, we use 
multiple indicators of psychosocial stress including stress from the work environment, family, 
and friends to operationalize psychosocial stress using a confirmatory factor analysis (CFA). The 
use of CFA in the measurement and quantification of psychosocial stress is preferred over the 
use of an aggregate score because this approach explicitly accounts for differential measurement 
error related to the different stress sub-scales yielding a more accurate and precise assessment of 
the underlying constructs [243, 244].  
 
Methods 
Study population 
We utilized data from the 2005 Kaiser Permanente Georgia (KPGA) Survey on Health and 
Healthy Behaviors. Study participants were working adults who at the time of the data collection 
in 2005 met the following inclusion criteria: (1) age 25-59 years; (2) diagnosed with DM but 
without major micro- or macro-vascular complications; (3) employed by one of the 100 largest 
private or public employer groups offering KPGA as an insurance option; (4) enrolled in KPGA; 
and (5) subscribed within the enrolled family. Only individuals who reported their race as 
African American (Black) or Caucasian (White) were included in the current study because other 
racial/ethnic groups represented a very small proportion of KPGA enrollees. KPGA Institutional 
Review Board reviewed and approved the study protocol. 
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Data and measures 
The survey instrument included items and scales that had previously been used in other studies 
and which had demonstrated reliability and validity [176, 181]. Data obtained from the 
participants’ survey were linked to their clinical information and pharmacy records from 2005 to 
2008.  
 
Dependent variable: The main dependent variable was eGFR. Using the serum creatinine (SCr) 
measures, the annual eGFR was estimated using the Modification of Diet in Renal Diseases 
(MDRD) equation [180]. 
 
𝒆𝑮𝑭𝑹 = 186 ∗ 𝑺𝑪𝒓−1.154 ∗ 𝑨𝒈𝒆−0.203 ∗ [1.210 𝑖𝑓 𝐵𝑙𝑎𝑐𝑘] ∗ [0.742 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒] 
Main independent variable: The main independent variable was psychosocial stress, assessed 
from two major sources; social settings (family and friends) and the work environment.  Social 
stress was assessed by two 4-item subscales: one reflecting friend/family support and the other 
measuring friend/family strain.  These subscales were adapted from the Midlife in the United 
States (MIDUS) study [176]. The MIDUS scales for family and friends are identical except for 
the reference (e.g., "How much do members of your family really care about you?" and "How 
much do your friends really care about you?"); therefore, we combined the references to create a 
single measure of social climate (e.g. "How much do your friends and family members really 
care about you?").  Each subscale was averaged and scaled from 0 (most strained, least 
supportive) to 100 (least strained, most supportive). The work-related psychosocial stress was 
assessed using the following 4 subscales from the MIDUS [176] study:  work decision authority 
(6 items), job demands (5 items), coworker support (2 items), and supervisor support (3 items).  
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Each item was assessed using a 5-response Likert scale: "All of the time", "Most of the time", 
"Sometimes", "Rarely", "Never".  Each subscale was averaged and scaled from 0 (most strained, 
least supportive) to 100 (least strained, most supportive) by transforming each item response 
from 0-100 (and reverse coding where necessary). 
 
Health-related covariates: Glycemic control was assessed using HbA1c measures from 
participants’ laboratory results from 2005 through 2008.  Data on height, weight, systolic blood 
pressure (SBP), and diastolic blood pressure (DBP) were obtained from medical records 
associated with participants’ primary care visits. Height and weight were used to compute body 
mass index (BMI).  SBP and DBP were used to compute mean arterial pressure (MAP).  A 
binary variable was created to indicate insulin use versus insulin non-use. For individuals using 
oral hypoglycemic (OH) agents, we estimated and included the proportion of days in 2005 with 
OH coverage. 
 
Other socio-demographic measures: Participants age (ranging between 25 and 59 years), and 
sex (male=0, female=1) were assessed from the KPGA computerized data. Race/ethnicity 
(Black=0, White=1), level of formal education (high school education or less=0, some college=1, 
college graduate=2, post-graduate=3), and marital status (married=0 and not married=1) were 
assessed from the survey. Individual level income information was generally not available and 
was not included in this study as a covariate.  Instead, we used the neighborhood-based 
socioeconomic status (SES), a validated census track-level scale comprised of 7 measures from 
the US Census as described by Roblin [181]. 
 
  
58 
 
Statistical analyses 
Descriptive statistics was performed in SAS software version 9.3 [182]. The percent missing on 
covariates ranged between 0 and 41% while the percent pairwise coverage for the covariates 
ranged between 0.39 and 1.00. The percent missing for the stress indicators ranged between 
0.5% and 1.6% with covariance coverage ranging between 0.98 and 1.00. For eGFR measures, 
49% had a measure on all four waves while 91% had at least a measure on two waves. To 
address the missingness on exogenous predictors, we performed multiple imputations (10 times) 
in SAS. We used this imputed data for both the measurement and the growth models. Other than 
the descriptive statistics, all analyses were performed in Mplus statistical software version 6.1 
[245].  Latent psychosocial stress variable was specified using confirmatory factor analysis 
(CFA) by loading the four work-related psychosocial stress indictors and the social environment 
stress indicator on the latent stress variable (Fig 1). An unconditional (no covariate) growth 
model was fit to the four eGFR waves. Without an a priori hypothesis about the functional form 
of the relationship between stress and eGFR over time, in the final conditional growth model, 
stress was specified with direct effects on the repeated measures to allow the greatest flexibility 
to obtain a time-varying effect estimates. We controlled for the annual HbA1c measures as a 
time varying covariate while socio-demographic variables (sex, age, race, education, 
neighborhood-based SES), smoking, BMI, insulin use, medication coverage (proportion of days 
covered by oral hypoglycemic agents), and MAP were controlled for as time invariant 
covariates. The robust maximum likelihood estimator was used. Statistical significance was 
determined at a two sided alpha level of 0.05. 
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Results and discussions 
Results 
Descriptive statistics 
The study included 575 participants with the mean age of 49.6 years (6.9 years). As shown on 
Table 1, slightly higher proportions of females and blacks made up the study sample. Individuals 
included in the study were highly educated and the majority were married. The prevalence of 
current smoking (16%) in the study sample was lower than the state smoking prevalence of 22% 
during 2005 [246].  The baseline mean eGFR was 83.2ml/min/1.73m2 (SD=21.3) while the mean 
psychosocial stress for the subscales ranged between 47.1 and 66.0. 
The measurement and the growth models: 
Measurement Model 
Using supervisor support to scale the factors, the unstandardized factor loadings ranged between 
0.106 and 0.787 (Table 3). The mean fit indices for the CFA model were: χ2 p-value <0.001, 
root-mean-square error of approximation (RMSEA) = 0.072 (90% CI=0.041-0.107), comparative 
fit index (CFI) = 0.951, Tucker Lewis index (TLI) =0.902 and Standardized Root Mean Square 
Residual (SRMR) =0.037. The mean factor score determinancy coefficient was 0.873 with 
values ranging between 0.869 and 0.878. The mean standardized residual variances of the stress 
sub-scales was each significant. Values ranged between 0.35 (Supervisor support) and 0.99 
(work demand) (Table 3). 
 
Structural Model 
The baseline model estimated an intercept parameter with time centered at 2005 (baseline) and a 
slope parameter that represented the annual mean rate of eGFR change during the four year study 
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period.  The model fit was adequate: χ2 p-value >0.001, RMSEA = 0.058 (90% CI=0.061-0.094), 
CFI = 0.94, TLI = 0.938, TLI=0.926 and SRMR=0.037. Significant variance existed in the 
intercept (σ2 = 360.77, p<0.001) and the slope (σ2 = 10.49, p<0.016) parameters. The mean 
intercept was 82.62 while the mean slope was 0.88 (p = 0.003) which was significantly different 
from zero. Table 3 contains both the unstandardized and the standardized estimates of the CFA 
model.  
The fit for the final conditional model to estimate the direct association between psychosocial 
stress and eGFR was also adequate: χ2 p-value >0.001, RMSEA = 0.048 (90% CI=0.041-0.055), 
CFI=0.916, TLI = 0.893 and SRMR=0.037. Psychosocial stress was not directly associated with 
any of the four measures of the eGFR. At the study baseline, age, race, MAP and insulin use 
were significantly associated with eGFR. Over time, MAP was associated with eGFR decline. 
Table 4 contains the estimates of the final growth model. 
 
Discussion 
Changes in renal function have been associated with increased risk of mortality [247, 248]. 
Adverse clinical outcomes such as cardiovascular events have also been associated with decline 
or rapid improvements in eGFR [249] [248].  Great variability exists in eGFR changes and may 
reflect in the variation in the onset and progression of DN [96]. Factors such as obesity, 
hypertension and dyslipidemia are associated with changes in renal function and psychosocial 
stress [250]. In the current study, we examined the direct association between changes in eGFR 
and psychosocial stress. We also examined other documented predictors of eGFR decline in this 
unique study population - white and black working adults with DM but without major micro- or 
macro-vascular complications. 
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Our primary hypothesis that psychosocial stress would be associated with eGFR was not 
supported in the final growth model. We did not observe an evidence of a direct association 
between psychosocial stress and eGFR. This null finding is consistent with the findings from the 
unique study by Tsurugano and colleagues, who did not find a direct association between job 
stress and CKD (eGFR <60mL/min/1.73 m2) [250]. A number of reasons may partly explain the 
null finding in the current study. First, psychosocial stress is a broad concept, spanning multiple 
facets of life including major life events, financial circumstances, perceived discrimination, 
social circumstances and the work-environment [237-239].  The current study included stress 
from two main sources – the work environment and social settings in creating the latent 
psychosocial stress factor. It is therefore possible that the current measure had underestimated 
the level of psychosocial stress in this population.  The measure might not have been 
comprehensive enough to assess all stressful situations in individuals that might predispose them 
to a decline in eGFR. Secondly, although our study participants were DM patients, they were 
relatively young (mean age of 49.9 years, SD=6.9) and healthy without a major micro or 
macrovascular complications at the time of the study in 2005 so changes in renal function may 
be slow. The rate of renal decline increases with age but the decline has been noted to accelerate 
after the age 50-60 years [251, 252]. Less than half of the study population was between the ages 
50-60 years old. Thirdly, a major predictor of renal decline among DM patients is poor glycemic 
control. Goel and Perkins have demonstrated that higher HbA1c increases eGFR loss, and 
observed the greatest decline among individuals with albuminuria [253]. The Diabetes Control 
and Complications Trial (DCCT), the Epidemiology of Diabetes Intervention and Complications 
(EDIC) study and a number of other studies have also made similar findings of the relationship 
between HbA1c and eGFR [86, 254-256]. During the four year study period, the mean HbA1c 
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remained virtually constant with values ranging between 7.9% and 8.1%. A marginal but 
significant improvement in eGFR was also observed among the study population. Although 
unexpected, particularly, among our population of DM patients, kidney function can be highly 
variable and may improve over time [209, 257]. Finally, the study participants were in an 
integrated delivery system of well-established DM management program and might have 
received special care to prevent or slow down eGFR decline [218]. 
Although, no direct association was observed between psychosocial stress and changes in eGFR, 
some of the study covariates were significantly associated with eGFR in the expected direction. 
These significant associations were important for two reasons; 1) validation of the variables in 
the data and 2) identification of factors that are important to changes in eGFR among this unique 
study population which could provide information that could guide prevention efforts, 
particularly, for factors that could be modified. At baseline, race, age, insulin use and MAP was 
each significantly related to eGFR. Blacks had lower eGFR values compared to their white 
counterparts. Racial differences in renal decline have been reported, with blacks experiencing the 
greatest disparity compared to whites [258, 259]. Increasing age has been associated with eGFR 
decline among adults with DM as has been adequately captured in the introductory part of this 
paper. The relationship between insulin use and renal decline is consistent with the literature as 
well [240]. Insulin use may be related to having had DM for a long time, and or poor glycemic 
control, particularly, among type 2 DM patients. Both factors have been associated with decline 
in renal function among DM patients [193, 260-262]. Increasing MAP was found to be 
associated with eGFR at both study baseline and over time, a finding that is consistent with 
several studies that have found high blood pressure to be closely associated with renal decline 
among DM patients [263-265]. Some interventional studies have also demonstrated that 
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antihypertensive treatment among DM patients may reduce the incidence or slow the progression 
of renal decline [266, 267]. As shown by Figure 1, the effect of MAP on eGFR trajectory over 
the four year period indicated that not only was people with higher MAP value started with lower 
eGFR value but also their rate of eGFR decline was faster. 
The strengths of the study need to be noted. First, to the best of our knowledge, this is the first 
study to examine the direct association between psychosocial stress as a latent factor and renal 
function over time among individuals with DM. The use of latent psychosocial stress factor 
reduced the measurement errors associated with the items used to create the latent factor [243, 
244]. Secondly, the study controlled for several covariates that could have an impact on renal 
function among individuals with DM including HbA1c level, blood pressure, smoking, 
medication coverage and demographic variables. Despite the study strengths, the following 
points need to be considered as study limitations – 1) our measure of psychosocial stress may be 
limited by the inclusion of fewer major sources; work and social environments; and 2) 
participants were enrollees of KPGA and results may not be generalizable to uninsured patients, 
those in other health insurance system or patients in other geographic locations.  
Conclusion 
 
In a study of fairly healthy adult DM patients, we did not find a direct association between 
psychosocial stress and eGFR. However, predictors of changes in eGFR among our study 
population were age, race, insulin use and blood pressure. Interventions to address renal decline 
among DM patients should address high blood pressure. Considering the inclusion of limited 
sources of psychosocial stress in creating the stress factor, future studies that would use a 
comprehensive measure of psychosocial stress are needed. 
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Tables and figures 
Table 3.1 – Selected characteristics of study sample 
 
*Mean and standard deviation 
 
 
 
 
 
 
 
 
 
 
 
Demographic Variable (n=575) Percent (n) 
Age (Years)- 2005 49.6(6.9)* 
Sex 
    Male 40.7% (234) 
   Female 59.3% (341) 
Race 
    White 45.9% (264) 
   Black 54.1% (311) 
Education 
    Less than HS 5.0 % (29) 
   HS Grad 19.1% (110) 
   Some College 36.4% (209) 
   College Grad 39.5% (227) 
Marital Status 
    Married 59.5% (342) 
   Not Married 40.5% (233) 
Current Smokers  
   Yes 15.8% 
   No 84.2% 
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Table 3.2. Health status-related characteristics of study sample 
Variable Mean (SD) 
Stress Sub-scales (2005) 
    Decision latitude 58.5 (24.4) 
   Work demands 47.1 (18.6) 
   Coworker Support 60.3 (21.8) 
   Supervisor Support 62.5 (24.1) 
   Social Stress 66.0 (17.8) 
eGFR 
    Year 2005 83.2 (21.3) 
   Year 2006 82.5 (25.2) 
   Year 2007 81.8 (22.0) 
   Year 2008 82.3 (23.3) 
HbA1c 
    Year 2005 8.1 (1.8) 
   Year 2006 8.0 (1.9) 
   Year 2007 7.9 (1.7) 
   Year 2008 8.0 (1.7) 
BMI (2005) 34.3 (7.3) 
MAP (2005) 114.3 (13.5) 
Proportion of days covered by oral agents in 
2005 0.79 (0.3) 
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Table 3.3 Estimates from the CFA and the unconditional growth models  
 
Estimate S.E. P-Value 
Standardized 
Estimate 
Stress-subscale     
   Supervisor Support 1.00 0.00 NA 0.81 
   Coworker Support 0.79 0.09 < 0.001 0.71 
   Decision Latitude 0.55 0.08 < 0.001 0.44 
   Work Demand 0.11 0.05 0.046 0.11 
   Social Stress 0.26 0.06 < 0.001 0.29 
     
Residual Variances     
   Supervisor Support 203.91 44.35 <0.001 0.35 
   Coworker Support 239.39 26.47 <0.001 0.50 
   Decision Latitude 479.12 33.85 <0.001 0.81 
   Work Demand 340.04 17.71 <0.001 0.99 
   Social Stress 270.85 19.06 <0.001 0.92 
     
eGFR Intercept Factor 
       Mean 82.62 0.88 < 0.001 4.351 
   Variance 360.77 4.34 < 0.001 1.00 
     eGFR Slope Factor 
       Mean  0.88 0.30 0.003 0.28 
   Variance 10.49 4.34 0.016 1.00 
     Intercept/Slope 
Covariance 2.63 8.29 0.751 0.05 
Mean Fit Indices for CFA Model: χ2 p-value >0.001; RMSEA 0.072 (90% CI=0.041-0.107); 
CFI=0.951; TLI=0.902; SRMR=0.037 
Mean Fit Indices for Unconditional growth model: χ2 p-value >0.001; RMSEA= 0.058 (90% 
CI=0.061-0.094); CFI=0.938; TLI=0.926; SRMR=0.037 
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Table 3.4. Covariates in the final model 
Variable Intercept (p-value) S.E (I)  Slope (p-value) S.E (S) 
SES Quartile -0.01 (0.994) 1.078 
 
0.27 (0.398) 0.316 
Education -1.29 (0.298) 1.242 
 
0.04 (0.902) 0.344 
Marital Status (0=NM) -0.91 (0.671) 2.129 
 
-0.69 (0.274) 0.63 
Smoking 1.03 (0.724) 2.925 
 
1.19 (0.184) 0.897 
BMI -0.10 (0.486) 0.138 
 
-0.02 (0.592) 0.039 
Insulin (0=non-use) -6.99 (0.003) 2.326 
 
-1.09 (0.127) 0.714 
Medication Coverage 0.71 (0.871) 4.39 
 
1.28 (0.290) 1.208 
MAP -0.24 (0.003) 0.08 
 
-0.10 (<0.001) 0.026 
Age -1.22 (<0.001) 0.159 
 
0.02 (0.634) 0.048 
Sex (0=Male) 0.66 (0.732) 1.913 
 
0.30 (0.585) 0.545 
Race (0=black) 7.45 (<0.001) 2.088 
 
-0.05 (0.933) 0.614 
NM=Not Married; S.E (I) = Standard Error of the Intercept; S.E (S) = Standard Error of the Slope 
Mean Fit Indices: χ2 p-value >0.001; RMSEA=0.048 (90% CI=0.041-0.055); CFI=0.902; TLI=0.876; 
SRMR=0.037 
 
 
 
Adjusted for age, sex, race, education, BMI, smoke, medication coverage, insulin use, psychosocial stress 
and glycemic control. Both the intercept and the slope were significantly different from each other. 
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Figure 3.1. Changes in eGFR at different values of MAP, controlling 
for other covariates 
Mean MAP Q3 value of MAP
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Adjusted for age, sex, race, education, BMI, smoke, medication coverage, MAP, psychosocial stress and 
glycemic control. Only the intercept was significantly different from each other.
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Figure 3.2.S Changes in eGFR over time, Insulin users vs 
non-users, controlling for other covariates 
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Adjusted for age, sex, education, BMI, smoke, medication coverage, insulin use, MAP, psychosocial stress 
and glycemic control. Both the intercept and the slope were significantly different from each other.  
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Figure 3.3.S Changes in eGFR over time, White vs Black, 
controlling for other covariates
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Abbreviations: eGFR=estimated glomerular filtration rate; A1c=glycosylated hemoglobin; BMI= body mass index; MAP= mean arterial 
pressure; Med Coverage= oral hypoglycemic agents coverage during 2005. 
 
Figure 3.4. Graphical representation of the final growth model 
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Abstract 
Objectives: In a racially diverse population, examine the association between: 1) blood 
pressure/hypertension and four markers of OS and 2) blood pressure/hypertension and oxidative 
balance score (OBS)  
Method: Using data (n=317) from the cross-sectional Study on Race, Stress and Hypertension 
(SRSH), an OBS was constructed from various measures of pro- and anti-oxidant exposures. OS 
was assessed by 4 biomarkers: fluorescent oxidative products, F2-Isoprostanes, mitochondrial 
DNA copy number and γ-tocopherol. Multivariable linear and logistic regression analyses were 
used to estimate the associations of interest. 
Results: In the final adjusted model, none of the OS markers was significantly associated with 
blood pressure/hypertension. OBS was inversely associated with hypertension after adjusting for 
study covariates. 
Conclusion: Persons with higher OBS are less likely to have hypertension; however the 
evidence on the relationship between OS markers and blood pressure remains unconvincing. 
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Introduction 
 
Hypertension is a common and costly disease [30, 268]. It significantly increases the risk 
of death and cardiovascular events such as stroke and heart attack [31, 269-272]. It is estimated 
that hypertension accounts for about 54% of all strokes and 47% of all ischemic heart disease 
cases worldwide [273]. In the US, the prevalence of hypertension is approximately 31% [30] 
with the annual direct medical cost of about $70 billion. This cost estimate is expected to triple 
by 2030 [31]. The traditional risk factors for hypertension include family history, age, physical 
inactivity, obesity, tobacco use, and excessive alcohol intake [32-34]. Evidence from recent 
studies has suggested the role of oxidative stress (OS) in the pathogenesis of hypertension [35-
37]. OS has thus, become a therapeutic target in hypertension treatment [161]. 
OS is defined as an imbalance between pro-oxidants and anti-oxidants in favor of the 
former [107].  OS results from overproduction of reactive oxygen and nitrogen species, which in 
turn damage essential biomolecules such as proteins, lipids and DNA. OS-induced damage has 
been implicated in several human illnesses [125-127]. Hypertension has been associated with 
higher levels of OS, although it remains unclear whether increased OS is a cause or a 
consequence of hypertension [128]. Most of the evidence supporting the relationship between 
OS and hypertension comes from basic science and animal studies [39-41]. In humans, however, 
the results have not been entirely consistent and efficacy of anti-oxidant supplementation in 
reducing blood pressure has not been shown in large clinical trials [42, 43]. 
OS cannot be directly observed in vivo, due to the short lifespan of reactive oxygen and 
nitrogen species, however, it can be evaluated in humans using biomarkers [160]. While some 
biomarkers of OS are non-specific, others measure a particular biological or chemical aspect of 
the process [161, 162]. In humans, the results on the association between OS and hypertension 
  
75 
 
have mostly been driven by the type of OS biomarker and population being studied [35]. One of 
the goals of the current study was therefore to estimate the association between OS and 
hypertension in a racially and ethnically diverse population using four biomarkers of OS: F2-
isoprotanes (F2-isoP)- a specific marker of lipid peroxidation [164], fluorescent oxidative 
products (FOP) – a non-specific marker that measures a mixture of analytes resulting from 
reactions of reactive oxygen species with lipids, proteins and or DNA [165], the number of 
copies of mitochondrial DNA (MtDNA) – a general marker of cumulative cellular damage [168, 
170]; and γ-tocopherol (γ-Toc) – a marker of metabolic response to OS [173]. 
One potential reason for the inconsistencies in the relationship between hypertension and 
OS-related exposures (e.g. antioxidant intake) in humans may be the complexity of the processes 
through which diet, lifestyle, and other factors impact blood pressure. Previous studies have 
proposed oxidative balance score (OBS), a measure of the status of pro- and anti-oxidants, to be 
a more accurate representation of the overall OS-related exposures in an individual [156, 159, 
175].  The current study therefore sought to build upon and expand on the existing literature. The 
specific objectives of the current study were to examine: 1) the relationship between 
hypertension and each of four biomarkers of OS and 2) the association between hypertension and 
OBS. 
 
Materials and Methods 
 
Study Population 
We used cross-sectional data from a previously conducted Study on Race, Stress and 
Hypertension (SRSH). The study was designed to assess the differences in dietary, lifestyle, and 
psychosocial exposures in relation to blood pressure in a racially and ethnically diverse 
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population. The methods of the study has been described in detail elsewhere [175]. Briefly, the 
study included individuals aged 25-74 years who self-identified as Non-Hispanic Whites 
(NHW), African Americans (AA) or West African Immigrants (WAI) and who were residents of 
Georgia. NHW and AA subjects were selected from among 800 participants in a previously 
completed feasibility phase of the Georgia Cohort Study (GCS). The WAI subjects were 
recruited de novo using previously established ties with Atlanta churches that included large 
proportions of WAI. The sample of GCS participants was selected after the completion of the 
WAI recruitment and frequency matched to WAI participants on age and sex. There were 335 
individuals who met the initial study inclusion criteria. Of this, 18 participants were excluded 
from the analyses; 7 had no value for hypertension and 11 were missing values for all four 
biomarkers of OS. All methods were reviewed and approved by the Institutional Review Boards 
of the Emory University and the Georgia State University. 
 
Questionnaire data 
The study-specific questionnaire provided data on demographic characteristics (age, sex, 
race/origin and education), medical history (hypertension and use of medications), and lifestyle 
(physical activity and smoking) for all participants. Blood pressure and anthropometric measures 
(height and weight) were also taken during data collection sessions. Self-administered 
questionnaires were returned during the data collection session. We used a previously validated 
tool for measuring physical activity [274].  The reported and measured BMI were highly 
correlated (r= 0.91). 
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Blood Samples 
All participants provided blood samples that were drawn into five 10mL vacutainer tubes 
(2 sodium heparin tubes, 1 EDTA tube, and 2 red top tubes for serum collection) and 
immediately plunged into ice and protected from direct light.  Plasma, serum, and buffy coat 
specimens were separated within 4-8 hours by centrifugation under refrigeration, aliquoted, 
frozen and stored at -80°C.  The aliquots were then shipped overnight on dry ice for molecular 
analysis by the Molecular Epidemiology and Biomarker Research Laboratory (MEBRL) at the 
University of Minnesota, Minneapolis, MN.   
 
Laboratory Analysis 
Plasma lycopene, α-carotene, β-carotene, β-cryptoxanthin, zeaxanthin, lutein, α-
tocopherol, and γ-tocopherol were measured by a high performance liquid chromatography 
(HPLC) assay using previously described methods [183-185].  Serum ferritin was measured by 
an antibody-based method using Roche 911 analyzer.  
Gas chromatography-mass spectrometry (GCMS) [161], a gold standard for the measurement of 
F2-isoP, was used to measure plasma free F2-isoP. The F2-isoP were extracted from the plasma 
sample with deuterium (4)-labeled 8-iso-prostaglandin F2 alpha as an internal standard.  
The measurement of FOP was performed using a modified Shimasaki  method [186], which has 
been previously described elsewhere [187].  A mixed solution was centrifuged for 10mins at 
3000rpm, 1mL of supernatant was added to cuvettes for spectrofluorometric readings, and a 
relative fluorescence intensity unit per milliliter of plasma was estimated using the 
spectrofluorometer [187]. Calibration was performed using standard quinine diluted in 0.1 
NH2SO4.  
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The copy number of MtDNA was determined using real-time quantitative PCR described 
by Shen et al [188].  Two primers were used, one for MtDNA and the other for nuclear DNA. 
The ratio of MtDNA and nuclear DNA was determined using serially diluted genomic sample 
DNA of a healthy referent [188]. 
 
Oxidative balance score 
The OBS was estimated using a priori selected 13 pro- and anti-oxidants components 
according to our previous study [175] and those of others [189, 190] as listed in Table 1. The 
score combined plasma micronutrient measurements and lifestyle behaviors. The plasma level of 
pro- and anti-oxidants, were divided into sex and race/origin specific tertiles. The number of 
minutes of physical activity per week was also divided into tertiles. For anti-oxidants (α-
carotene, β-carotene, β-cryptoxanthin, zeaxanthin, lutein, α–tocopherol) and physical activity, the 
first to third tertiles were assigned scores of 0-2. For pro-oxidants (ferritin), the first to third 
tertile were assigned a score of 2-0 respectively. To maintain scoring consistency, we assigned 
scores of 0-2 to the other categorical OBS components. We assigned a score of 0-2 for obese 
(BMI ≥30kg/m2), overweight (BMI=25-29.99kg/m2) and normal weight (BMI <25kg/m2) 
respectively. For smoking or alcohol use: never-smokers or never-drinkers received a score of 
two; former smokers and former drinkers or those with missing information received a score of 
one; and current smokers and current drinkers received a score of zero.  For NSAIDs and aspirin, 
zero points were assigned to participants who reported no regular use of these medications, one 
point to those who did not report usage or were missing information, and two points to those who 
reported regular use. Regular users for both aspirin and NSAID were defined as individuals who 
were taking these medications at least once every week. The points assigned to each component 
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were summed up to represent the overall OBS. OBS was categorized into three approximately 
equal intervals; 3-10, 11-17 and 18-25 representing low, medium and high OBS, respectively. 
OBS was also used in a separate analysis as a continuous variable. 
 
Blood Pressure and Hypertension 
Trained and certified staff took the blood pressure measures. After participants had rested 
for about five minutes seated, three blood pressure measures were taken with at least a minute 
interval using mercury sphygmomanometry and appropriately sized arm cuffs. The mean of the 
three blood pressure measures was estimated and used in this study. Systolic and diastolic blood 
pressure (SBP and DBP) measures were expressed as separate continuous variables.  Individuals 
were considered hypertensive if they met any of the following conditions; (a) ever been told by a 
health care professional that s/he has hypertension, (b) self-reported antihypertensive medication 
use, (c) had systolic blood pressure (SBP) equal or greater than 140mmHg (c) had diastolic blood 
pressure (DBP) equal or greater than 90mmHg.  
 
Statistical Analysis 
The F2-isoP, FOP, MtDNA and γ-Toc were each dichotomized into a ‘low’ and ‘high’ 
using their respective sex and race/origin specific median as the cut-off. SBP and DBP were 
modeled as continuous variables. Hypertension was dichotomized (hypertensive and 
normotensive). OBS was used as both a continuous and a three level categorical variable.  
The first series of statistical analyses examined the association between SBP, DBP and each of 
the OS markers and OBS as continuous variables in linear regression models. In the second set 
of analyses, we examined the association of hypertension with OBS and with each biomarker of 
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OS, using categorical definitions of the outcome. The odds ratios (OR) for the continuous OS 
variables in the logistic equation was each scaled to their respective one standard deviation.  For 
oxidative stress markers, each linear and logistic regression model adjusted for race/origin, age, 
sex, education and BMI. For analyses involving OBS, we did not control for BMI because it was 
included in the score. 
All analyses were performed using pairwise deletion method as the default (Method 1). 
To estimate the effect of missing data, sensitivity analyses were performed by imputing the 
missing values. We imputed in two different fashions: 1) using five times multiple imputation 
method available in SAS and 2) by replacing missing values with sex and race specific mean. All 
models were assessed for collinearity among independent variables and goodness of fit.  All 
estimated measures of association were accompanied by 95% confidence intervals (CI).  
Statistical significance was determined at two sided p-value of <0.05. All analyses were 
performed in SAS statistical software version 9.3 [182]. 
 
Results 
 
The study population included 100 (32.5%) WAI, 121 (39.3%) NHW, and 87 (28.3%) 
AA participants. Approximately 33% of the study participants were hypertensive. Hypertension 
was more common in AA (45.2%) than in NHW (33.1%) and WAI (24.0%) participants. 
Varying number of participants had a measure for each of the four biomarkers of OS; F2-isoP 
(n=221), FOP (n=266), MtDNA (n=173), and γ-Toc (n=278). 
Among the participants, most (60.3%) were females and more than a third had a college 
degree (41.9%, Table 2). About 32% were current alcohol users and 5% were current cigarette 
smokers. Individuals with hypertension were older and more likely to use aspirin and NSAID 
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regularly. As expected, individuals with hypertension had significantly higher BMI compared to 
their normotensive counterparts (Table 2). Inter-individual variability for OS markers was 
greatest for FOP (range 0.01-0.21 expressed as average standard reference adjusted) and F2-isoP 
(range 14.5-280.1 pg/mL): these two biomarkers showed approximately 20-fold difference 
between the lowest and the highest values. Other OS biomarkers and OBS did not vary as much 
within the study population: the ranges for the values were 1.22-5.57 expressed as relative copy 
numbers for MtDNA, 0.06-0.56 mg/dL for γ-Toc, and 4.0-24.0 for OBS. OBS was inversely but 
not statistically significantly correlated with F2-isoP (r= -0.18), MtDNA (r= -0.08) and γ-Toc (r= 
-0.04).  By contrast correlation between OBS and FOP was positive (r= 0.30) and statistically 
significant (Table 3). 
In the linear regression models evaluating the relationship between blood pressure and 
each of the OS markers and OBS, increasing levels of γ-Toc were associated with increasing 
levels of SBP (β=22.27, p=0.0150) and DBP (β=14.76, p=0.0120) in the crude analyses, but the 
results were attenuated and no longer statistically significant after adjusting for study covariates. 
MtDNA copy number was also inversely associated with DBP (β=-2.32, p=0.0123) in the crude 
but not in the adjusted model. The other OS markers and OBS were not associated with blood 
pressure in the crude or the adjusted models. The sensitivity analyses were consistent with the 
original results except for FOP and F2-isoP that changed direction in some instances; however all 
before- and after-imputation results were statistically non-significant (Table 4). 
In the logistic regression models that used hypertension as the binary outcome variable, 
the associations with the OS biomarkers were in the hypothesized direction but none of the 
results were statistically significant after controlling for covariates. Sensitivity analyses did not 
substantially affect the results. 
  
82 
 
There was a statistically significant association between OBS and hypertension after 
controlling for race/origin, age, sex and education. The adjusted OR for middle and higher 
categories of OBS vs. lower category (reference) were 0.30 (95% CI=0.13-0.72) and 0.17 (95% 
CI=0.03-0.95) respectively. For the continuous OBS, the adjusted OR was 0.87 (95% CI=0.79-
0.96). In the sensitivity analyses, the results for the continuous OBS were similar to the original 
analyses but the associations with categorized OBS were substantially attenuated (Table 5).  
 
Discussion 
 
Hypertension is a major public health problem in most parts of the world. It is highly 
prevalent and considered a major risk factor for cardiovascular diseases. Endothelial dysfunction, 
defined as a shift in endothelium actions towards reduced vasodilation, pro-inflammatory and 
pro-thrombotic state has been associated with the pathophysiology of hypertension [133]. 
Although the underlying mechanism to endothelial dysfunction is complex and multifactorial, 
current evidence indicates that OS may be a key factor in this process [275]. An area of recent 
hypertension management research is in the therapeutic intervention that target OS [161, 275]. 
This approach requires an in-depth understanding of the complex role of OS in the pathogenesis 
of hypertension.  In the present cross-sectional study, we examined the relationship between high 
blood pressure and OS and OBS, hypothesizing that higher level of OS and lower levels of OBS 
would be associated with high blood pressure/hypertension.  
We found increasing levels of γ-Toc to be associated with higher SBP/DBP and higher 
odds of being hypertensive; although the association was less evident in the multivariable 
analyses. Cooney and colleagues [173] have characterized γ-Toc as an antioxidant defense 
indicator whose level may increase to reflect the metabolic response to OS. Consistent with this 
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characterization, we also found a statistically significant positive correlation between γ-Toc and 
F2-isoP, a validated marker of OS [163] . Jiang and colleagues have also associated γ-Toc and its 
metabolites with anti-inflammatory function and found their levels to rise in response to 
inflammatory signals [276, 277]. γ-Toc enhances cellular immune response by protecting cells 
against damaging effects of endogenous nitric oxide (NO) generation [278] while enhancing 
cellular NO synthesis [279].  These data indicate the important physiologic functions of γ-Toc, 
particularly, in relation to OS [173].  
The findings from the final models did not support our hypothesis that increasing levels 
of OS markers would be associated with high blood pressure, although, we found the adjusted 
associations to be in the hypothesized direction. This null finding is consistent with other clinical 
studies that reported no significant difference in OS levels among individuals with and without 
hypertension [280, 281].  
The observed association between OBS and high blood pressure/hypertension supported 
our second hypothesis that higher OBS levels would be inversely related to high blood pressure. 
This finding is consistent with other studies that also noted an inverse relationship between OBS 
and poor health including all-cause mortality [156] and colorectal adenoma [159].  Several 
previous studies found an inverse association between some of the OBS components and blood 
pressure [129, 282-284]. For example Li and Xu recently concluded from a meta-analysis that 
lycopene supplementation reduces systolic blood pressure [285]. Chen and colleagues also found 
lower levels of both α- and β-carotenes in persons with hypertension [286].  
The use of dietary anti-oxidants to reduce blood pressure is plausible because these compounds 
have been shown to reduce the bioavailability of reactive oxygen species, increase production of 
nitric oxide (NO), down-regulate nicotinamide adenine dinucleotide phosphate (NADPH) 
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oxidase and up-regulate endothelial NO synthase (eNOS) [36, 287]. Higher production and 
bioavailability of NO in the endothelial cells is important for vascular relaxation [135, 136, 139]. 
Despite compelling evidence from experimental biology studies, the findings from clinical 
studies of the effect of anti-oxidant supplementation for blood pressure reductions have not 
produced desired results [43, 288]. The possible reasons for the discrepancy in the use of anti-
oxidants to treat conditions related to oxidative stress have been articulated in a number of 
reviews [154, 155, 289]. With respect to hypertension, Montezano and Touyz identified three 
reasons for the discrepancy between anti-oxidants supplementation and reduction in blood 
pressure: the type of antioxidants used; patient cohorts; and the trial design [36].  One other 
possible reason is that anti-oxidants in diets are mixed and work as continuous chain while 
supplementations are usually a couple of specific anti-oxidants and therefore, may lack this anti-
oxidants chain. Also, it has been found that if an antioxidant is not restored by the next in the 
chain after scavenging ROS, it begins to act as a pro-oxidant [153]. The evidence therefore 
suggests that biochemical interactions exist among antioxidants which may be lacking in 
supplements due to the use of one or two individual antioxidants [154, 155].  
Given the inconsistent relationship between OS markers and high blood 
pressure/hypertension and the inconclusive association between individual anti-oxidants and 
high blood pressure/hypertension from previous studies, the use of OBS seems promising, as it 
represents the overall patterns of pro- and anti-oxidant exposures.  
An important methodological feature of the present study is the use of a racially and 
ethnically diverse population.  This allowed for assessing multiple biomarkers of OS and their 
relation to each other and to hypertension in US born whites and blacks and in West Africans.  In 
addition, the use of plasma levels of micro-nutrients in this study may accurately represent 
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current intake and availability of pro- and anti-oxidants compared to food frequency 
questionnaire-derived measures [290]. The major limitation of this study is the missing 
information on several variables used in the analyses.  Although sensitivity analyses did not 
affect the overall conclusions, some of the results changed following imputation of missing data.  
 
Conclusion 
 
The presented results suggest that higher OBS may be inversely associated with 
hypertension, a finding that is consistent with several previous studies.  By contrast after 
controlling for confounders, markers of OS were not associated with blood pressure or 
hypertension.  The discrepancy between relatively consistent associations observed for pro- anti-
oxidant exposures and largely null results for markers of OS indicate that OS-related lifestyle 
and dietary factors may act through other mechanisms.  The observed results need to be 
confirmed in independently conducted, preferably longitudinal, studies.  If these findings are 
indeed confirmed, the mechanisms by which OBS may influence the risk of hypertension need to 
be explored further.   
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Tables and figures 
Table 4.1. OBS Assignment 
Component Score Assignment 
Plasma Zeaxanthin 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Plasma Cryptoxanthin 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Plasma Lycopene 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Plasma α-carotene 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Plasma β-carotene 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Plasma α-tocopherol 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Serum Ferritin 2=low (1st tertile), 1=medium (2nd tertile), 0=high (3rd tertile) 
Physical Activity 0=low (1st tertile), 1=medium (2nd tertile), 2=high (3rd tertile) 
Alcohol use 0=current drinker, 1=former drinker/missing, 2=never drinker 
Smoking 0=current smoker, 1=former smoker/missing, 2=never smoked 
Aspirin use 0=no regular user, 1=unknown/missing, 2=regular user 
NSAID use 0=no regular user, 1=unknown/missing, 2=regular user 
Obesity 0=obese,  1=overweight, 2=normal weight 
NSAID = Non-steroidal anti-inflammatory drugs. Normal weight=BMI<25kg/m2, overweight=BMI between 25.0-
29.9kg/m2, Obese=BMI ≥30kg/m2.  
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Table 4.2. Distribution of main study variables 
 
 
Hypertensive and Normotensive Compared 
Demographic 
Characteristics  
Overall 
(n=317) 
Hypertensive  
(n=106) 
 
Normotensive  
(n=211) 
 
p-value 
  Age 
 
47.1 ( 11.9 ) 
 
54.2 (10.6) 43.5 (10.9) 
 
<0.001 
  Female (%) 
 
60.3 
 
64.2 
 
58.3 
 
0.3206 
  Race 
 
          WAI 
 
32.5 
 
23.1 
 
37.3 
 
0.0064 
   NHW 
 
39.3 
 
38.5 
 
39.7 
     AA 
 
28.3 
 
38.5 
 
23.0 
  Education 
 
           Less than HS 
 
6.8 
 
3.9 
 
8.3 
 
0.0495 
    HS Grad 
 
16.1 
 
23.1 
 
12.6 
      Some College 
 
35.2 
 
36.5 
 
34.5 
      College Grad 
 
41.9 
 
36.5 
 
44.7 
  OBS Measures 
 
         Current Alcohol User (%) 
 
32.2 
 
29.3 
 
33.7 
 
0.2065 
  Current Smoking (%) 
 
5.0 
 
5.1 
 
5.0 
 
0.0856 
  Obesity (%)  44.3  68.9  31.7  <0.001 
  Regular Aspirin User (%) 
 
23.3 
 
45.6 
 
12.9 
 
<0.001 
  Regular NSAID User (%) 
 
26.6 
 
32.5 
 
23.8 
 
0.1545 
  Plasma Zeaxanthin, ug/dL 
 
20.9 ( 10.5 ) 
 
22.6 (11.4) 
 
20.1 (10.0) 
 
0.0572 
  Plasma Cryptoxanthin, ug/dL 7.7 ( 9.1 ) 
 
8.5 (14.4) 
 
7.4 (4.8) 
 
0.3164 
  Plasma Lycopene, ug/dL 
 
45.3 ( 24.9 ) 
 
38.7 (18.6 
 
48.4 (27.0) 
 
0.0021 
  Plasma α-carotene, ug/dL 
 
11 ( 15.1 ) 
 
8.6 (13.2) 
 
12.2 (15.9) 
 
0.0604 
  Plasma β-carotene, ug/dL 
 
22.5 ( 23 ) 
 
19.2 (18.9) 
 
24.1 (24.6) 
 
0.0901 
  Plasma α-tocopherol, ug/dL 
 
0.96 ( 0.28 ) 
 
1.0 (0.3) 
 
0.9 (0.3) 
 
0.0012 
  Serum Ferritin, ug/dL 
 
128.1 ( 226.5 ) 
 
141.0 (135.2) 
 
121.8 (259.9) 
 
0.5009 
  OBS Score 
 
12.2 ( 3.8 ) 
 
12.0 (4.2) 
 
12.4 (3.6) 
 
0.4407 
Biomarkers 
 
         γ-Toc (mg/dL) 
 
0.2 ( 0.09 ) 
 
0.22 (0.09) 
 
0.19 (0.09) 
 
0.0206 
  F2-isoP (pg/mL) 
 56.6 ( 34.87 ) 
 
63.5 (43.8) 
 
53.1 (29.0) 
 
0.037 
  FOP (Av Std Ref Adj) 
 
0.04 ( 0.02 ) 
 
0.05 (0.03) 
 
0.04 (0.02) 
 
0.2015 
  MtDNA (rel copy number) 
 
3.2 ( 0.83 ) 
 
3.15 (0.73) 
 
3.19 (0.88) 
 
0.7746 
Blood Pressure  
 
         SBP (mmHg) 
 
124.0 ( 14 ) 
 
132.7 (14.1) 
 
119.7 (11.7) 
 
<0.0001 
  DBP (mmHg) 
 
76.3 ( 9.2 ) 
 
78.9 (9.6) 
 
75.1 (8.7) 
 
0.0004 
  BMI (kg/m2) 
 
29.8 ( 6.6 ) 
 
33.0 (6.7) 
 
28.4 (5.9) 
 
<0.0001 
For continuous variables, t-test was used to test the difference between hypertensive and normotensives while chi-
square test was used for categorical variables. Av Std Ref Adj= Average standard reference adjusted. 
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Table 4.3. Correlations between OS markers and OBS; Spearman are above diagonal and 
Pearson are below the diagonal 
 
FOP F2-isoP MtDNA γ-Toc OBS 
FOP 1 -0.32** -0.02 -0.15** 0.37** 
F2-isoP -0.17** 1 -0.15 0.40** -0.11 
MtDNA -0.01 -0.14 1 -0.12 -0.10 
γ-Toc -0.15** 0.36** -0.15 1 -0.02 
OBS 0.31** -0.16 -0.09 -0.01 1 
FOP = florescent oxidation products; F2-isoP = F2-isoprostanes; MtDNA = mitochondrial DNA copy number; γ-Toc 
= gamma tocopherol; OBS = oxidative balance score.  
** p<0.05 
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Table 4.4. Association between Blood Pressure and FOP, F2-isoP, MtDNA and G-Toc 
 
Method 1 (OR, 95% CI) 
 
Method 2 (OR, 95% CI) 
 
Method 3 (OR, 95% CI) 
Crude Adjusted 
 
Crude Adjusted 
 
Crude Adjusted 
SBP 
           FOP  76.12 (0.0901) 73.5 (0.0829) 
 
70.33 (0.1142) 59.60 (0.1560) 
 
76.32 (0.0865) 71.79 (0.0881) 
   F2-isoP  0.02 (0.4146) -0.04 (0.2145) 
 
0.02 (0.5611) -0.02 (0.4366) 
 
-0.01 (0.9350) -0.04 (0.0752) 
   MtDNA -2.39 (0.0802) -1.94 (0.1627) 
 
-1.26 (0.2973) -0.79 (0.4601) 
 
-2.65 (0.0355) -1.66 (0.1857) 
   γ-Toc  22.27 (0.0150) 6.72 (0.4786) 
 
24.19 (0.0099) 7.53 (0.4367) 
 
22.6 (0.0151) 6.02 (0.5231) 
   OBS  0.40 (0.1353) 0.12 (0.6284) 
 
0.47 (0.0619) 0.21 (0.3950) 
 
0.61 (0.0083) 0.37 (0.0981) 
DBP 
           FOP  -12.94 (0.650) 23.98 (0.3962) 
 
-5.93 (0.8385) 22.08 (0.4116) 
 
-16.00 (0.5844) 22.41 (0.4330) 
   F2-isoP  0.02 (0.2544) -0.02 (0.1601) 
 
0.01 (0.4485) -0.01 (0.6329) 
 
0.01 (0.5110) -0.02 (0.2408) 
   MtDNA  -2.32 (0.0123) -0.44 (0.6356) 
 
-1.14 (0.1561) -0.28 (0.7099) 
 
-2.26 (0.0062) -0.39 (0.6498) 
   γ-Toc  14.76 (0.0120) 2.73 (0.6690) 
 
18.25 (0.0028) 4.47 (0.4826) 
 
14.44 (0.0180) 1.04 (0.8707) 
   OBS  0.25 (0.1342) 0.13 (0.4100) 
 
0.12 (0.5509) 0.05 (0.8022) 
 
0.21 (0.1750) 0.13 (0.3660) 
Method 1= Original data used pairwise deletion, Method 2= Used multiple imputation to handle missing data, Method 3= Replace missing information with race 
and sex specific mean. FOP=fluorescent oxidative products; F2-isoP = F2-isoprostanes; MtDNA=mitochondrial DNA copy number; γ-Toc= γ-tocopherol; Crude 
=OR without controlling for any covariate. Adjusted = OR after adjusting for age, sex, race/origin, education and BMI (when predictor was not OBS).  Each 
biomarker was dichotomized based on sex and race/origin specific median.  
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Table 4.5. The association between hypertension and FOP, F2-isoP, MtDNA, γ-Toc and OBS 
 
Method 1 (OR, 95% CI) 
 
Method 2 (OR, 95% CI) 
 
Method 3 (OR, 95% CI) 
 
Crude Adjusted 
 
Crude Adjusted 
 
Crude Adjusted 
FOP  
           Low Ref Ref 
 
Ref Ref 
 
Ref Ref 
   High 1.29 (0.78-2.15) 1.23 (0.66-2.29) 
 
1.16 (0.89-1.51) 1.09 (0.81-1.49) 
 
1.23(0.76-1.97) 0.09 (0.60-1.96) 
   FOP (Cont, 1-SD) 1.17 (0.91-1.51) 1.23 (0.85-1.78) 
 
1.16 (0.91-1.47) 1.12 (0.86-1.63) 
 
1.17 (0.91-1.51) 1.22 (0.85-1.75) 
F2-isoP  
           Low Ref Ref 
 
Ref Ref 
 
Ref Ref 
   High 1.28 (0.73-2.23) 1.00 (0.50-2.00) 
 
1.20 (0.74-1.94) 1.02 (0.74-1.40) 
 
1.03 (0.64-1.65) 0.95 (0.54-1.69) 
   F2-isoP (Cont, 1-SD) 1.33 (1.07-1.76) 0.97 (0.64-1.47) 
 
1.01 (1.00-1.01) 1.00 (0.99-1.01) 
 
1.20 (0.93-1.54) 0.97 (0.65-1.45) 
MtDNA 
           Low Ref Ref 
 
Ref Ref 
 
Ref Ref 
   High 1.32 (0.70-2.47) 1.33 (0.61-2.91) 
 
1.16 (0.90-1.49) 1.18 (0.87-1.61) 
 
1.41 (0.86-2.33) 1.35 (0.68-2.70) 
   MtDNA (Cont, 1-SD 0.95 (0.69-1.31) 0.96 (0.64-1.45) 
 
1.04 (0.71-1.54) 1.09 (0.73-1.62) 
 
0.96 (0.71-1.31) 1.00 (0.67-1.50) 
γ-Toc  
           Low Ref Ref 
 
Ref Ref 
 
Ref Ref 
   High 1.54 (0.94-2.55) 0.78 (0.41-1.47) 
 
1.23 (0.96-1.58) 0.91 (0.67-1.25) 
 
1.45 (0.91-2.32) 0.83 (0.45-1.50) 
   γ Toc (Cont, 1-SD) 1.33 (1.04-1.69) 0.99 (0.71-1.36) 
 
1.32 (1.04-1.66) 1.03 (0.03-33.43) 1.33 (1.04-1.69) 0.99 (0.72-1.36) 
OBS 
           Low (4-10) Ref Ref 
 
Ref Ref 
 
Ref Ref 
   Medium (11-17) 0.61 (0.31-1.19) 0.30 (0.13-0.72) 
 
0.92 (0.59-1.43)  0.89 (0.53-1.49) 
 
0.70 (0.42-1.17) 0.58 (0.31-1.08) 
   High (18-25) 0.50 (0.13-1.97) 0.17 (0.03-0.95) 
 
0.82 (0.39-1.71) 0.56 (0.22-1.43) 
 
0.85 (0.29-2.48) 0.46 (0.12-1.73) 
   Continuous 0.95 (0.87-1.03) 0.87 (0.79-0.96) 
 
0.96 (0.90-1.03) 0.91 (0.84-0.99) 
 
0.98 (0.91-1.04) 0.93 (0.86-1.00) 
Method 1= Original data used pairwise deletion, Method 2= Used multiple imputation to handle missing data, Method 3= Replaced missing information with 
race and sex specific mean. FOP=fluorescent oxidative products; F2-isoP = F2-isoprostanes; MtDNA=mitochondrial DNA copy number; γ-Toc= γ-tocopherol; 
Crude =OR without controlling for any covariate. Adjusted = OR after adjusting for age, sex, race/origin, education and BMI (when predictor was not OBS).  
Each biomarker was dichotomized based on sex and race/origin specific median. Con, 1-SD= Continuous variable scaled to 1 standard deviation. 
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CHAPTER 5. DISCUSSIONS AND FUTURE DIRECTIONS 
 
Overview of findings 
The goal of this dissertation was to investigate the associations between (1) psychosocial stress 
and glycemic control, (2) psychosocial stress and changes in renal function over time, and (3) 
oxidative stress (OS) and hypertension among adults. 
In the first study, a longitudinal data from Kaiser Permanente Georgia (KPGA) on Health and 
Healthy behaviors was used to examine the relationship between baseline psychosocial stress at 
the work environment and glycemic control. I applied both cross-sectional and longitudinal data 
analytic approach to examine this relation. Contrary to our expectation, we did not find a 
significant association between work-related psychosocial stress at baseline and glycemic control 
either at baseline or over time after controlling for study covariates. 
In the second study, the same longitudinal data from KPGA as was in the first study was used to 
examine the association between general measures of psychosocial stress and changes in 
estimated glomerular filtration rate (eGFR) over a period of four years. The results did not 
support our hypothesis that higher psychosocial stress would be associated with changes in 
eGFR over time after controlling for study covariates. However, age, race, insulin use and blood 
pressure were found to be associated with renal decline among our study population. 
In the third study, using data from the Study on Race, Stress and Hypertension, I examined the 
association between hypertension and: 1) OS markers (F2-Isoprostanes, Flourescent oxidative 
products, Copy number of mitochondrial DNA and γ-tocopherol); and 2) oxidative balance score 
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(OBS). As expected, OBS was inversely associated with hypertension but no significant 
association was observed between OS and hypertension. 
The results from the first two studies did not support our hypothesized association between 
psychosocial stress and the glycemic control and renal decline. Although, the results from both 
studies were consistent with the unique studies conducted to date on each topic, the null finding 
may partly be due to the measure of the psychosocial stress variable. The psychosocial stress 
concept is broad and encompasses stress from multiple sources. The use of psychosocial stress 
from only two major sources might have underestimated the extent of stress in the study 
population to observe an effect on DM management or decline in renal function among the study 
population. Studies that comprehensively assess psychosocial stress from diverse sources and 
further examine their relationship with a health outcome is limited. Due to the complex nature of 
the psychosocial stress concept and the multiple sources from which it could originate, future 
studies need to consider including stress from other sources including major life event, other 
existing chronic conditions, poverty and family circumstances. 
In the third study, the first hypothesis that OS would be positively associated with hypertension 
was not supported but the second hypothesis that OBS would be inversely associated with OBS 
was supported. If the OBS and hypertension association is confirmed by future studies then the 
mechanism through which OBS impact hypertension need to be explored further. Also, although, 
the association between OS markers and hypertension was not significant in the final model after 
controlling for study covariates, each of the relationship was in the hypothesized direction. We 
observed low correlations between the markers of OS, although, these markers are assumed to be 
measuring the same concept, confirming the earlier suggestions that different OS markers may 
be explaining different aspects of the OS process and each may be independent from each other.  
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Implications for Future Research 
The assessment of a comprehensive psychosocial stress is difficult. This is due to the broad 
nature of the concept of psychosocial stress. In this study, we used psychosocial stress from two 
major sources, which was identified as a limitation, because it might not be comprehensive 
enough.  Future studies need to have a comprehensive assessment of psychosocial stress by 
including stress from multiple and diverse sources. Secondly, the study noted that psychosocial 
stress is personal, and response to stress may be impacted by several other factors such as 
culture, religion, race/ethnicity, the number of times experienced the stress, and the source of 
stress such as poverty, major life events, abuse or trauma [65-68, 291]. In the light of the 
individual variations in perception and response to stress, we propose that the assessment of 
psychosocial stress in future studies give consideration to the following: (1) assess past life 
experiences which have been identified to feed into stress perception and response [64]; (2) 
assess resiliency which can be used to adjust for the perception piece, a factor considered to 
mediate the relationship between stressful situation and health; and (3) control for contextual 
factors such as culture, religion, and race/ethnicity, which have been identified to play a 
significant role in response to psychosocial stress.  
Our proposal for future studies to assess and include psychosocial stress from multiple sources 
would also mean the need to apply the appropriate statistical procedures and tools that would 
accurately combine psychosocial stress from those multiple sources. It was obvious from the 
literature that stress from different sources assesses different aspects of the psychosocial stress 
process, therefore, the use of statistical approach that will combine the different sources while 
controlling for measurement errors would be critical in future psychosocial stress research. Such 
statistical approach would include but not limited to the use of confirmatory factor analysis and 
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latent class analysis in combination with structural equation modeling. Another fact observed in 
the literature was that psychosocial stress from different sources might have varying impact on 
health. The implication of this finding is that future studies that combine psychosocial stress 
from multiple sources should also consider assigning weight to stress from different sources to 
reflect their impact on health based on the literature.  
In the third study, the observed low correlations between the markers of OS, albeit these markers 
assessing the same process, might suggest that the markers are rather formative of the process of 
OS rather than a reflective, which is what has always been assumed to be the case. Future 
studies, particularly, those that will combine multiple OS markers as a latent factor should do so 
in the formative framework. The finding of an association between OBS and hypertension was 
important as most research that have utilized OBS as a way of comprehensively assessing the 
overall oxidative burden did so in relation to cancer. To our knowledge, this is the first study to 
examine the association between OBS and hypertension. More future studies, particularly, 
longitudinal studies, need to further examine the OBS and hypertension association. If this 
association is confirmed, then the mechanism through which OBS may relate to hypertension 
would need to be examined as well.  
Finally, given what is known about γ –tocopherol level and the relationship with hypertension 
observed in this study, future studies need to examine the role of this compound in the 
pathophysiology of hypertension.
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